The Pennant Group, Inc. (PNTG) 10-K 4 Mar 20 2019 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 04, 2020	Jun. 30, 2019
Cover page.
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	001-38900
Entity Registrant Name	THE PENNANT GROUP, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-3349931
Entity Address, Address Line One	1675 East Riverside Drive
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Eagle
Entity Address, State or Province	ID
Entity Address, Postal Zip Code	83616
City Area Code	(208)
Local Phone Number	506-6100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	PNTG
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,885,252
Entity Public Float			$ 0
Entity Central Index Key	0001766400
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false

CONSOLIDATED AND COMBINED BALAN

CONSOLIDATED AND COMBINED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 402	$ 41
Accounts receivable—less allowance for doubtful accounts of $677 and $616, respectively	32,183	24,469
Prepaid expenses and other current assets	6,098	4,613
Total current assets	38,683	29,123
Property and equipment, net	14,644	10,458
Right-of-use assets (Note 13)	316,328
Escrow deposits	1,400	0
Restricted and other assets	1,955	2,464
Intangible assets, net	45	78
Goodwill	41,233	30,892
Other indefinite-lived intangibles	33,462	25,136
Total assets	447,750	98,151
Current liabilities:
Accounts payable	8,653	4,390
Accrued wages and related liabilities	16,343	12,786
Lease liabilities—current (Note 13)	12,285
Other accrued liabilities	13,911	12,371
Total current liabilities	51,192	29,547
Long-term lease liabilities—less current portion (Note 13)	304,044
Other long-term liabilities	2,877	3,316
Long-term debt, net	18,526	0
Total liabilities	376,639	32,863
Commitments and contingencies
Equity:
Common stock, $0.001 par value; 100,000 shares authorized; 28,435 and 27,853 shares issued and outstanding at December 31, 2019, respectively.	28	0
Additional paid-in capital	74,882	0
Accumulated deficit	(3,799)	0
Net parent investment	0	55,856
Noncontrolling interest	0	9,432
Total equity	71,111	65,288
Total liabilities and equity	$ 447,750	$ 98,151

CONSOLIDATED AND COMBINED BAL_2

CONSOLIDATED AND COMBINED BALANCE SHEETS (Parenthetical) $ in Thousands	Dec. 31, 2019USD ($)$ / sharesshares
Statement of Financial Position [Abstract]
Allowance for doubtful accounts | $	$ 677
Common stock, par value (in dollars per share) | $ / shares	$ 0.001
Common stock, shares authorized (in shares)	100,000,000
Common stock, shares issued (in shares)	28,435,000
Common stock, shares outstanding (in shares)	27,853,000

CONSOLIDATED AND COMBINED STATE

CONSOLIDATED AND COMBINED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue	$ 338,531	$ 286,058	$ 250,991
Expense
Cost of services	258,941	212,421	187,278
Rent—cost of services (Note 13)	34,975
Rent—cost of services (Note 13)		31,199	31,304
General and administrative expense	35,135	18,843	14,463
Depreciation and amortization	3,810	2,964	2,544
Total expenses	332,861	265,427	235,589
Income from operations	5,670	20,631	15,402
Other income (expense):
Interest expense, net	(410)	0	0
Income before provision for income taxes	5,260	20,631	15,402
Provision for income taxes	2,085	4,352	5,375
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total	3,175	16,279	10,027
Less: net income attributable to noncontrolling interest	629	595	160
Net income and other comprehensive income attributable to The Pennant Group, Inc.	$ 2,546	$ 15,684	$ 9,867
Earnings per share (Note 4):
Basic (in dollars per share)	$ 0.11	$ 0.58	$ 0.36
Diluted (in dollars per share)	$ 0.11	$ 0.58	$ 0.36
Weighted average common shares outstanding:
Basic (in shares)	27,838	27,834	27,834
Diluted (in shares)	29,586	27,834	27,834

CONSOLIDATED AND COMBINED STA_2

CONSOLIDATED AND COMBINED STATEMENTS OF STOCKHOLDERS' EQUITY AND NET PARENT INVESTMENT - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Net Parent Investment	Non-Controlling Interest
Equity, beginning balance (in shares) at Dec. 31, 2016		0
Equity, beginning balance at Dec. 31, 2016	$ 48,360	$ 0	$ 0	$ 0	$ 46,902	$ 1,458
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling interest attributable to subsidiary equity plan	1,364				(1,938)	3,302
Net income attributable to noncontrolling interest	160					160
Net transfer from parent	165				165
Net income attributable to The Pennant Group, Inc.	9,867				9,867
Equity, ending balance (in shares) at Dec. 31, 2017		0
Equity, ending balance at Dec. 31, 2017	59,916	$ 0	0	0	54,996	4,920
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling interest attributable to subsidiary equity plan	1,378				(2,539)	3,917
Net income attributable to noncontrolling interest	595					595
Net transfer from parent	(12,285)				(12,285)
Net income attributable to The Pennant Group, Inc.	15,684				15,684
Equity, ending balance (in shares) at Dec. 31, 2018		0
Equity, ending balance at Dec. 31, 2018	65,288	$ 0	0	0	55,856	9,432
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling interest attributable to subsidiary equity plan	594				(2,991)	3,585
Stock repurchase related to subsidiary equity plan	(394)					(394)
Net income attributable to noncontrolling interest	629					629
Net transfer from parent	11,894				11,894
Net income attributable to The Pennant Group, Inc.	2,546			(3,799)	6,345
Cash distribution to Parent	(11,600)				(11,600)
Reclassification of invested equity	137		72,893		(59,504)	(13,252)
Issuance of common stock after spin-off (in shares)		27,834
Issuance of common stock at Spin-Off	0	$ 28	(28)
Issuance of common stock at Spin-Off	1,987		1,987
Exercise of stock options, issuance of other awards after spin-off (in shares)		601
Exercise of stock options, issuance of other awards after the Spin-Off	30		30
Equity, ending balance (in shares) at Dec. 31, 2019		28,435
Equity, ending balance at Dec. 31, 2019	$ 71,111	$ 28	$ 74,882	$ (3,799)	$ 0	$ 0

CONSOLIDATED AND COMBINED STA_3

CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net income	$ 3,175	$ 16,279	$ 10,027
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,810	2,964	2,544
Amortization of deferred financing fees	78	0	0
Provision for doubtful accounts	858	346	3,374
Share-based compensation	3,382	2,382	2,298
Non-cash leasing arrangement (Note 13)	220
Deferred income taxes	79	0	0
Change in operating assets and liabilities:
Accounts receivable	(8,571)	(2,569)	(5,707)
Prepaid expenses and other assets	(2,746)	(210)	113
Operating lease obligations	(2,081)
Accounts payable	4,069	1,373	432
Accrued wages and related liabilities	3,376	1,583	2,708
Other accrued liabilities	1,720	398	199
Other long-term liabilities	2,185	729	1,262
Net cash provided by operating activities	9,554	23,275	17,250
Cash flows from investing activities:
Purchase of property and equipment	(6,714)	(3,603)	(3,133)
Cash payments for business acquisitions	(18,760)	(4,725)	(12,059)
Cash payments for asset acquisitions	(20)	(593)	0
Cash proceeds received on sale of intangibles	0	0	500
Cash proceeds from the sale of assets	0	0	121
Escrow deposits	(1,400)	0	0
Restricted and other assets	429	(556)	(1,512)
Net cash used in investing activities	(26,465)	(9,477)	(16,083)
Cash flows from financing activities:
Proceeds from sale of subsidiary shares	2,293	1,972	0
Repurchase of subsidiary shares	(2,687)	(1,972)	0
Net investment from/(to) parent	10,788	(13,793)	(1,161)
Cash distribution to parent in connection with Spin-Off	(11,600)	0	0
Proceeds from revolver agreement	42,500	0	0
Payments on revolver agreement	(22,500)	0	0
Payments for deferred financing costs	(1,552)	0	0
Issuance of common stock upon the exercise of options	30	0	0
Net cash provided by/(used in) financing activities	17,272	(13,793)	(1,161)
Net increase in cash	361	5	6
Cash beginning of period	41	36	30
Cash end of period	402	41	36
Cash paid during the period for:
Interest	156	0	0
Income taxes	120	0	0
Lease liabilities	37,088
Non-cash financing and investing activity:
Capital expenditures	946	$ 717	$ 309
Right-of-use assets obtained in exchange for new operating lease obligations	9,059
Adjustment to right-of-use assets and lease liabilities from lease modifications	$ 77,462

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF BUSINESS The Pennant Group, Inc. (herein referred to as “Pennant,” the “Company,” “it,” or “its”), is a holding company with no direct operating assets, employees or revenue. The Company, through its independent operating subsidiaries, provides healthcare services across the post-acute care continuum. As of December 31, 2019, the Company’s subsidiaries operated 63 home health, hospice and home care agencies and 52 senior living communities located in Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. On October 1, 2019, The Ensign Group, Inc. (NASDAQ: ENSG) (“Ensign” or the “Parent”) completed the separation of Pennant (the “Spin-Off”). To accomplish the Spin-Off, Ensign contributed the Company’s assets and liabilities into Pennant and distributed to Ensign’s stockholders all of the outstanding shares of Pennant common stock. Each Ensign stockholder received a distribution of one share of Pennant common stock for every two shares of Ensign’s common stock, plus cash in lieu of fractional shares. Additionally, the noncontrolling interest was converted into shares of Pennant at the established conversion ratio. As a result of the Spin-Off on October 1, 2019, Pennant began trading as an independent company on the NASDAQ under the symbol “PNTG.” Certain of the Company’s subsidiaries, collectively referred to as the Service Center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to the operations through contractual relationships. Each of the Company’s affiliated operations are operated by separate, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities is not meant to imply, nor should it be construed as meaning, that Pennant has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by Pennant.

BASIS OF PRESENTATION AND SUMMA

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation - The accompanying consolidated and combined financial statements of the Company (the “Financial Statements”) reflect the Company’s financial position, results of operations and cash flows as the business was operated as part of Ensign prior to the Spin-Off, and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the regulations of the Securities and Exchange Commission (“SEC”). Prior to the Spin-Off, the combined financial statements were prepared on a stand-alone basis and derived from the consolidated financial statements and accounting records of Ensign. Management believes that the Financial Statements reflect, in all material respects, all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position, results of operations, and cash flows for the periods presented in conformity with GAAP applicable to the annual period. All intercompany transactions and balances between the various legal entities comprising the Company have been eliminated in consolidation. The consolidated and combined statements of income reflect income that is attributable to the Company and the noncontrolling interest. The Company consists of various limited liability companies and corporations established to operate home health, hospice, home care, and senior living operations. The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Revenue was derived from transactional information specific to the Company’s services provided. The costs in the consolidated and combined statements of income reflect direct costs and allocated costs prior to the Spin-Off. Estimates and Assumptions - The preparation of Financial Statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, cost allocations, intangible assets and goodwill, right-of-use assets and lease liabilities for leases greater than 12 months, and income taxes. Actual results could differ from those estimates. Revenue Recognition - On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“Topic 606”) applying the modified retrospective method. The adoption of Topic 606 did not have a material impact on the measurement nor on the recognition of revenue of contracts, for which all revenue had not been recognized, as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of retained earnings at the beginning of 2018. See Note 5 , Revenue and Accounts Receivable . Cost Allocation - The Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior to the Spin-Off on October 1, 2019. Such allocations include, but are not limited to, executive management, accounting, human resources, information technology, compliance, legal, payroll, insurance, tax, treasury, and other general and administrative items. These costs were allocated to the Company on a basis of revenue, location, employee count, or other measures. These cost allocations are reflected within general and administrative expense in the consolidated and combined statements of income, including for share-based compensation expenses disclosed in Note 12 , Options and Awards . The amount of general and administrative costs allocated prior to October 1, 2019, inclusive of share-based compensation expense, was $23,710. The amount of general and administrative costs, inclusive of share-based compensation, allocated for the years ended December 31, 2018 and 2017 were $18,843 and $14,463, respectively. Management believes the basis on which the expenses were allocated to be a reasonable reflection of the services provided to the Company during the periods. Ensign’s external debt and related interest expense were not allocated to the Company for any of the periods presented as no portion of the borrowings were assumed by the Company as part of the Spin-Off. All interest incurred by the Company was subsequent to the Spin-Off. Prior to the Spin-Off, employees of the Company’s subsidiaries participated in Ensign’s equity-based incentive plans (the “Ensign Plans”) and the Cornerstone Subsidiary Equity plan (the “Subsidiary Equity Plan”). Share-based compensation includes the expense attributable to employees of the Company’s subsidiaries who participated in the Ensign Plans, as well as the allocated cost related to Ensign subsidiaries’ employees that participated in the Ensign Plans. Share-based compensation related to Ensign subsidiaries’ employees that participated in the Ensign Plans were allocated on the basis of revenue. All share-based compensation related to the Subsidiary Equity Plan was recognized in the Financial Statements and, therefore, no cost allocation was necessary. Prior to the Spin-Off, share-based compensation costs associated with the Subsidiary Equity Plan awards was initially measured at fair value at the grant date and was expensed as non-cash compensation over the vesting term. Historically, these awards were granted once per year and the fair value has been determined by an independent valuation of the subsidiary shares. The valuation incorporated a discounted cash flow analysis combined with a market-based approach to determine the fair value of the subsidiary equity. Cash and cash equivalents - Cash and cash equivalents consist of bank term deposits and therefore approximates fair value. The Company places its cash with high credit quality financial institutions. Prior to the Spin-off the Company participated in a cash management program with Ensign where net cash activity was included in the net parent investment. Accounts Receivable and Allowance for Doubtful Accounts - Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. Property and Equipment - Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three Impairment of Long-Lived Assets - The Company reviews the carrying value of long-lived assets that are held and used in the independent operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiary to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and the Company did not identify any asset impairment during the years ended December 31, 2019, 2018 and 2017. Intangible Assets and Goodwill - Definite-lived intangible assets consist primarily of patient base and customer relationships. Patient base is amortized over a period of four months to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition when acquired. Customer relationships are amortized between one seven The Company’s indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2019, 2018 and 2017. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Given the time it takes to obtain pertinent information, the initial fair value might not be finalized at the time of the reported period. Accordingly, it is not uncommon for the initial estimates to be subsequently revised. The Company recorded goodwill and other intangible assets at the operation level when acquired, and as such, these assets are identifiable specifically to the subsidiaries of Pennant. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any impairment charge during the years ended December 31, 2019, 2018 and 2017. See further discussion at Note 9, Goodwill and Intangible Assets, Net . Fair Value of Financial Instruments - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. The Company determines fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. Income Taxes - Prior to the date of the Spin-off, the Company’s operations have been included in Ensign’s U.S. federal and state income tax returns and all income taxes have been paid by subsidiaries of Ensign. Also prior to the date of the Spin-off, income tax expense and other income tax related information contained in these Financial Statements were presented using a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company was a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts are reasonable. However, the Company’s Financial Statements may not necessarily reflect its income tax expense or tax payments in the future, or what tax amounts would have been if the Company had been a stand-alone company for the entire period presented. Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ. Noncontrolling Interest - Prior to the Spin-Off, the Company presented the noncontrolling interest and the amount of consolidated net income attributable to the Company in its Financial Statements. The carrying amount of the noncontrolling interest was adjusted by an allocation of subsidiary earnings based on ownership interest prior to the Spin-Off. The noncontrolling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off and thus, will no longer be allocated a portion of earnings . Share-Based Compensation - The Company measures and recognizes compensation expense for all share-based payment awards, including employee stock options, made to employees and Pennant’s directors based on estimated fair values, ratably over the requisite service period of the award. The Company accounts for forfeitures as they occur. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables. The total amount of share-based compensation was $3,382, $2,382, and $2,298 for the years ended December 31, 2019, 2018 and 2017, respectively, of which $2,769, $1,900 and $1,823, respectively, was recorded in general and administrative expense. For further discussion see Note 12, Options and Awards. Invested Capital - The net parent investment on the consolidated and combined balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off. Earnings Per Share - For all prior periods presented, the earnings per share included on the accompanying Consolidated and Combined Statements of Income was calculated based on the 27,834 shares of Pennant common stock distributed on October 1, 2019 in conjunction with the Spin-Off, including shares related to the conversion of the noncontrolling interest. Prior to October 1, 2019, Pennant did not have any issued and outstanding common stock. The same number of shares was used to calculate basic and diluted earnings per share since no Pennant employee equity awards were outstanding prior to the Spin-Off. In connection with the Spin-Off, shares of existing equity awards were replaced with shares under the new Pennant awards and are reflected in basic and diluted net income per share for the year ended December 31, 2019. For further discussion see Note 4, Computation of Net Income Per Common Share. Recent Accounting Pronouncements - Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration. Recent Accounting Standards Adopted by the Company Leases and Leasehold Improvements - The Company leases senior living communities and commercial office space. In February 2016, the FASB established Topic 842, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines. On January 1, 2019, the Company adopted ASC Topic 842, Leases (“Topic 842”), using the modified retrospective transition method. Leases for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 840, Leases (“Topic 840” ). The Company has elected the package of practical expedients permitted under the transition guidance which allows us to not reassess (1) initial direct costs, (2) lease classification for existing or expired leases, and (3) lease definition for existing or expired contracts as of the effective date of January 1, 2019. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheets and recognize those lease payments in the condensed combined statements of income on a straight-line basis over the lease term. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. Operating leases are included in operating lease assets, current operating lease liabilities and noncurrent operating lease liabilities on the Company's consolidated and combined balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term excludes lease renewals because the renewal rents are not at a bargain, there are no economic penalties for the Company not to renew the lease, and it is not reasonably assured that the Company will exercise the extension options. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements. The adoption of this standard resulted in recognition of right-of-use assets and lease liabilities of $240,090 and $241,453, respectively, on the Company’s combined balance sheet as of January 1, 2019. Neither net deferred tax assets nor equity were impacted as a result of the adoption of this standard. The standard did not materially affect its consolidated and combined net earnings or have a notable impact on liquidity. See further discussion at Note 13, Leases . Prior to the adoption of Topic 842, the Company recognized revenue related to its senior living residency agreements in accordance with the provisions of Topic 840. Subsequent to the adoption of Topic 842, lessors are required to separately recognize and measure the lease component of a contract with a customer utilizing the provisions of Topic 842 and the non-lease components utilizing the provisions of Topic 606, Revenue from Contracts with Customers. To separately account for the components, the transaction price is allocated among the components based upon the estimated stand-alone selling prices of the components. Additionally, certain components of a contract which were previously included within the lease element recognized in accordance with Topic 842 prior to the adoption of Topic 842 (such as common area maintenance services, other basic services, and executory costs) are recognized as non-lease components subject to the provisions of Topic 606 subsequent to the adoption of Topic 842. Entities are required to recognize a cumulative effect adjustment to beginning retained earnings as of the initial application date of Topic 842 for changes to amounts recognized for these certain components for the transition from Topic 840 to Topic 606. However, entities are permitted to elect the practical expedient under ASU 2018-11, Leases (“ASU 2018-11”), allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. Entities that elect to utilize the lease/non-lease component combination practical expedient under ASU 2018-11 upon initial application of Topic 842 are required to apply the practical expedient to all new and existing transactions within a class of underlying assets that qualify for the expedient as of the initial application date with a cumulative effect adjustment to beginning retained earnings as of the initial application date for any changes recognized related to existing transactions. Upon adoption of Topic 842, the Company elected the lessor practical expedient within ASU 2018-11. The Company recognizes revenue under resident agreements based upon the predominant component, either the lease or non-lease component, of the contracts rather than allocating the consideration and separately accounting for it under Topic 842 and Topic 606. The Company has concluded that the non-lease components of the agreements governing its senior living communities are the predominant component of the contract; therefore, the Company recognizes revenue for these agreements under Topic 606. The timing and pattern of revenue recognition is substantially the same as that in effect prior to the adoption of Topics 606 and 842. Stock Compensation - In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (“ASU 2018-07”), which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of ASC Topic 718, Compensation-Stock Compensation (“Topic 718”), to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606. The Company adopted ASU 2018-07 effective January 1, 2019. The adoption of ASU 2018-07 did not have a material impact on Interim Financial Statements and related disclosures. Accounting Standards Recently Issued but Not Yet Adopted by the Company Financial Accounting Standards Board, or FASB, Accounting Standards Update, or ASU, 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” or ASU 2018-13 - In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company’s fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. FASB ASU, 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” or ASU 2017-04 - In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new guidance eliminates “Step 2” from the traditional two-step goodwill impairment test and redefines the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount, to a measure comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or “Step 2” of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company’s fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. FASB ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” or ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ( “Topic 326”), which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. Topic 326 will be effective for fiscal years beginning after December 15, 2019, which will be the Company’s fiscal year 2020, and early adoption is permitted. The Company is performing its valuation and does not expect the standard to have a material impact on our consolidated financial statements.

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT	RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT The Financial Statements include a combination of stand-alone and combined business functions between Ensign and the Company’s subsidiaries prior to the Spin-Off. The Company leases 29 of its senior living communities from subsidiaries of Ensign, each of the leases have a term of between 14 and 16 years from the lease commencement date. The total amount of rent expense included in Rent - cost of services paid to subsidiaries of Ensign was $11,292, $10,363 and $11,364 for the years ended December 31, 2019, 2018 and 2017, respectively. For further discussion on the modification of these leases subsequent the Spin-Off on October 1, 2019, see Note 13, Leases . Certain related party activity occurred as the Company’s subsidiaries received services from Ensign’s subsidiaries. Services included in cost of services were $3,166, $2,996, and $3,023 for the years ended December 31, 2019, 2018 and 2017, respectively. The consolidated and combined balance sheets of the Company include Ensign assets and liabilities that are specifically identifiable or otherwise attributable to the Company and were transferred to the Company in connection with the Spin-Off. Transactions that have occurred between subsidiaries of the Company and subsidiaries of Ensign are considered to be effectively settled at the time the transaction is recorded. The net effect of these transactions, including the cash management, is included in the consolidated and combined statements of cash flows as “Net investment from/(to) Parent”. Other related party activity with Ensign On October 1, 2019, in connection with the Spin-Off, Pennant entered into several agreements with Ensign that set forth the principal actions taken or to be taken in connection with the Spin-Off and govern the relationship of the parties following the Spin-Off, including the following: • Master Separation Agreement: the Company entered into a Master Separation Agreement with Ensign prior to the distribution of shares of the Company’s common stock to Ensign stockholders. The Master Separation Agreement provides for the allocation of assets and liabilities between the Company and Ensign and establishes certain rights and obligations between the parties following the Distribution (the “Master Separation Agreement”); • Transition Services Agreement: provides that for a limited time, Ensign is to provide the Company, and the Company is to provide Ensign, with certain services to ensure an orderly transition following the Spin-Off, including: human resources, accounting, legal and compliance, IT, office facilities, and other general support. Generally, the term for the provision of services under the agreement extends for no longer than two five • Tax Matters Agreement: provides that Pennant is responsible for indemnifying Ensign for a percentage of tax liabilities related to the Spin-Off and adjustments to the combined entity in the pre-distribution period (the “Tax Matters Agreement"). It also provides that Pennant will reimburse Ensign for tax benefits Pennant recognizes in connection with certain Pennant share based awards held by Ensign employees. The Company has recognized $291 in tax benefits related to the Tax Matters Agreement for the year ended December 31, 2019 and has recorded a payable to Ensign in connection with this amount; • Employee Matters Agreement: governs the parties’ obligations with respect to certain employee-related liabilities and certain employee benefit plans, programs, policies and other related matters for employees of Pennant (the “Employee Matters Agreement”); • Master Lease Agreement: provides for the owned real property and leased space allocated to Ensign or us, or in certain cases shared by Ensign and us, as the case may be, in a manner that is consistent with the different business uses and needs of Ensign and us (the “Master Lease Agreement”).

COMPUTATION OF NET INCOME PER C

COMPUTATION OF NET INCOME PER COMMON SHARE	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
COMPUTATION OF NET INCOME PER COMMON SHARE	COMPUTATION OF NET INCOME PER COMMON SHARE Basic and diluted net income per share are computed by dividing net income by the weighted average number of outstanding common shares during the period. In the basic and diluted earnings per share calculations, net income is equal to net income attributable to The Pennant Group, Inc. adjusted to include net income attributable to noncontrolling interest. Net income attributable to the noncontrolling interest has been included in the numerator for all periods as the non-controlling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off . On October 1, 2019, the distribution date, Ensign stockholders received one share of Pennant common stock for every two shares of Ensign’s common stock held as of the record date. The total shares distributed to the Ensign Group stockholders was 26,674. Additionally, concurrent with the Spin-Off the noncontrolling subsidiary interest converted into 1,160 shares of Pennant. The total number of common shares distributed on October 1, 2019 of 27,834 is being utilized for the calculation of basic and diluted earnings per share for all prior periods, as no common stock was outstanding prior to the date of the Spin-Off. In conjunction with the Spin-Off, outstanding options and unvested restricted stock awards held by employees of the Company were modified and replaced with Pennant awards. Additionally, the Company issued new options and restricted stock awards to Pennant and Ensign employees under the 2019 Omnibus Incentive Plan (the “OIP”) and Long-Term Incentive Plan (the “LTIP”) which were not included in the computation of basic and diluted earnings per share for any periods prior to the Spin-Off. Beginning in the fourth quarter, the dilutive impact of outstanding options and equity incentive awards are reflected in diluted net income per share using the treasury stock method. See further discussion at of the Company’s equity incentive plans in Note 12, Options and Awards . The following table sets forth the computation of basic and diluted net income per share for the periods presented: Year Ended December 31, 2019 2018 2017 Numerator: Net income attributable to The Pennant Group, Inc. $ 2,546 $ 15,684 $ 9,867 Add: net income attributable to noncontrolling interests 629 595 160 Net Income $ 3,175 $ 16,279 $ 10,027 Denominator: Weighted average shares outstanding for basic net income per share 27,838 27,834 27,834 Plus: incremental shares from assumed conversion (a) 1,748 — — Adjusted weighted average common shares outstanding for diluted income per share 29,586 27,834 27,834 Earnings Per Share: Basic net income per common share $ 0.11 $ 0.58 $ 0.36 Diluted net income per common share $ 0.11 $ 0.58 $ 0.36 (a) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were immaterial for the year ended December 31, 2019.

REVENUE AND ACCOUNTS RECEIVABLE

REVENUE AND ACCOUNTS RECEIVABLE	12 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer and Accounts Receivable [Abstract]
REVENUE AND ACCOUNTS RECEIVABLE	REVENUE AND ACCOUNTS RECEIVABLERevenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct within the context of the contract. Additionally, there may be ancillary services which are not included in the rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known. Revenue from the Medicare and Medicaid programs accounted for 55.6%, 53.1%, and 51.4% of the Company’s revenue for the years ended December 31, 2019, 2018 and 2017, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. Disaggregation of Revenue The Company disaggregates revenue from contracts with its patients by reportable operating segments and payors. The Company has determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in Note 5, Revenue and Accounts Receivable . The Company’s service specific revenue recognition policies are as follows: Home Health Revenue Medicare Revenue Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments. The Company adjusts Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and the Company’s estimate of the average percentage complete based on visits performed. Non-Medicare Revenue Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. Non-episodic Based Revenue - Revenue is recognized on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable. Hospice Revenue Revenue is recognized on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are calculated as daily rates for each of the levels of care the Company delivers. Revenue is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and an increase to other accrued liabilities. Senior Living Revenue The Company has elected the lessor practical expedient within Topic 842 and recognizes, measures, presents, and discloses the revenue for services rendered under the Company’s senior living residency agreements based upon the predominant component, either the lease or non-lease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements each have the same timing and pattern of transfer. The Company recognizes revenue under Topic 606 for its senior residency agreements, for which it has determined that the non-lease components of such residency agreements are the predominant component of each such contract. The Company’s senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered. Revenue by payor for the years ended December 31, 2019, 2018 and 2017, is summarized in the following tables: Year Ended December 31, 2019 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 47,819 $ 93,933 $ — $ 141,752 41.9 % Medicaid 6,575 10,061 29,819 46,455 13.7 Subtotal 54,394 103,994 29,819 188,207 55.6 Managed care 27,711 1,536 — 29,247 8.6 Private and other (a) 18,837 152 102,088 121,077 35.8 Total revenue $ 100,942 $ 105,682 $ 131,907 $ 338,531 100.0 % (a) Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations. Year Ended December 31, 2018 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 42,091 $ 73,906 $ — $ 115,997 40.5 % Medicaid 4,680 7,729 23,624 36,033 12.6 Subtotal 46,771 81,635 23,624 152,030 53.1 Managed care 23,541 918 — 24,459 8.6 Private and other (a) 16,067 105 93,397 109,569 38.3 Total revenue $ 86,379 $ 82,658 $ 117,021 $ 286,058 100.0 % (a) Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations. Year Ended December 31, 2017 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 36,592 $ 61,422 $ — $ 98,014 39.0 % Medicaid 4,398 6,832 19,813 31,043 12.4 Subtotal 40,990 68,254 19,813 129,057 51.4 Managed care 21,058 765 — 21,823 8.7 Private and other (a) 10,997 339 88,775 100,111 39.9 Total revenue $ 73,045 $ 69,358 $ 108,588 $ 250,991 100.0 % (a) Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations. Balance Sheet Impact Included in the Company’s consolidated and combined balance sheets are contract assets, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities as of December 31, 2019 and December 31, 2018, or activity during years ended December 31, 2019 and 2018. Accounts receivable as of December 31, 2019 and December 31, 2018 is summarized in the following table: December 31, 2019 December 31, 2018 Medicare $ 17,822 $ 11,457 Medicaid 6,579 6,692 Managed care 4,380 3,079 Private and other 4,079 3,857 Accounts receivable, gross 32,860 25,085 Less: allowance for doubtful accounts (677) (616) Accounts receivable, net $ 32,183 $ 24,469 Practical Expedients and Exemptions As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs (“Topic 340”), and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.

BUSINESS SEGMENTS

BUSINESS SEGMENTS	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
BUSINESS SEGMENTS	BUSINESS SEGMENTS The Company classifies its operations into the following reportable operating segments: (1) home health and hospice services, which includes the Company’s home health, hospice and home care businesses; and (2) senior living services, which includes the operation of assisted living, independent living and memory care communities. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations. Our Chief Executive Officer and President, who is our Chief Operating Decision Maker “CODM”, reviews financial information at the operating segment level. We also report an “all other” category that includes general and administrative expense from our Service Center. As of December 31, 2019, the Company provided services through 63 affiliated home health, hospice and home care agencies, and 52 affiliated senior living operations. The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. The Company’s Service Center provides various services to all lines of business. The Company does not review assets by segment and therefore assets by segment are not disclosed below. Beginning in the third quarter of 2019, in anticipation of the Spin-Off, the GAAP segment measure of profit and loss was changed from Segment Income (Loss) Before Provision for Income Taxes to Adjusted Segment EBITDAR from Operations. Prior period presentation has been revised to reflect the new measurement. Segment Adjusted EBITDAR from Operations is net income attributable to the Company's reportable segments excluding the interest expense, provision for income taxes, depreciation and amortization expense, rent, and, in order to view the operations performance on a comparable basis from period to period, certain adjustments including: (1) costs at start-up operations, (2) share-based compensation, (3) acquisition related costs, (4) transaction costs, (5) redundant and nonrecurring costs associated with the transition services agreement, (6) operating results of closed operations, and (7) net income attributable to noncontrolling interest. General and administrative expenses are not allocated to the reportable segments, and are included as “All Other”, accordingly the segment earnings measure reported is before allocation of corporate general and administrative expenses. The Company’s Chief Operating Decision Maker (“CODM”) uses Segment Adjusted EBITDAR from Operations as the primary measure of profit and loss for the Company's reportable segments and to compare the performance of its operations with those of its competitors. The Company's segment measures may be different from the calculation methods used by other companies and, therefore, comparability may be limited. The Company’s segment measures may be different from the calculation methods used by other companies and, therefore, comparability may be limited. The following table presents certain financial information regarding our reportable segments, general and administrative expenses are not allocated to the reportable segments and are included in “All Other” for the years ended December 31, 2019, 2018 and 2017: Home Health and Hospice Services Senior Living Services All Other Total Year Ended December 31, 2019 Revenue $ 206,624 $ 131,907 $ — $ 338,531 Segment Adjusted EBITDAR from Operations $ 33,354 $ 47,344 $ (18,591) $ 62,107 Year Ended December 31, 2018 Revenue $ 169,037 $ 117,021 $ — $ 286,058 Segment Adjusted EBITDAR from Operations $ 26,427 $ 47,230 $ (16,191) $ 57,466 Year Ended December 31, 2017 Revenue $ 142,403 $ 108,588 $ — $ 250,991 Segment Adjusted EBITDAR from Operations $ 21,007 $ 44,230 $ (12,643) $ 52,594 The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to income from operations: Year Ended December 31, 2019 2018 2017 Segment Adjusted EBITDAR from Operations $ 62,107 $ 57,466 $ 52,594 Less: Depreciation and amortization 3,810 2,964 2,544 Rent—cost of services 34,975 31,199 31,304 Adjustments to Segment EBITDAR from Operations: Less: Costs at start-up operations (a) 483 129 478 Share-based compensation expense (b) 3,382 2,382 2,298 Acquisition related costs (c) 665 — — Spin-off related transaction costs (d) 13,219 756 — Transition services costs (e) 532 — — Operating results of closed operations (f) — — 728 Add: Net income attributable to noncontrolling interest 629 595 160 Consolidated and Combined Income from Operations $ 5,670 $ 20,631 $ 15,402 (a) Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations. (b) Share-based compensation expense incurred which is included in cost of services and general and administrative expense. (c) Acquisition related costs that are not capitalizable. (d) Costs incurred related to the Spin-Off are included in general and administrative expense. (e) A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent Investment ) identified as redundant or nonrecurring that are included in general and administrative expense. Total fees under incurred under the Transition Services agreement were $2,982 for the year ended December 31, 2019.

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
ACQUISITIONS	ACQUISITIONS The Company’s acquisition focus is to purchase or lease operations that are complementary to the Company’s current businesses, accretive to the Company’s business or otherwise advance the Company’s strategy. The results of all the Company’s independent operating subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. 2019 Acquisitions During the year ended December 31, 2019, the Company expanded its operations with the addition of two home health agencies, five hospice agencies, two home care agencies and two senior living operations. In connection with the acquisitions of one of the senior living communities, the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. The Company did not acquire any material assets or assume any liabilities. A subsidiary of the Company entered into a separate operations transfer agreement with the prior operator of each acquired operation as part of each transaction. The addition of these operations added a total of 143 operational senior living units to be operated by the Company’s independent operating subsidiaries. The aggregate purchase price for these acquisitions was $18,780. The fair value of assets for all home health, hospice and home care acquisitions was concentrated in goodwill and as such, these transactions were classified as business combinations in accordance with ASC Topic 805, Business Combinations (“Topic 805”). The purchase price for the business combinations was $18,760, which mostly consisted of goodwill of $10,341 and indefinite-lived intangible assets of $8,326 related to Medicare and Medicaid licenses. The fair value of assets for the senior living acquisitions were concentrated in intangible assets and as such, these transactions were classified as an asset acquisition. The purchase price for the asset acquisitions was $20. The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of December 31, 2019. Acquisition costs related to the business combinations of home health, hospice, and home care was $611 during the year ended December 31, 2019. 2018 Acquisitions During the year ended December 31, 2018, the Company expanded its operations with the addition of four home health agencies, two hospice agency, two home care agency and seven senior living operations. The Company did not acquire any material assets or assume any liabilities other than the tenant’s post-assumption rights and obligations under the senior living long-term leases. The aggregate purchase price for these acquisitions during the year ended December 31, 2018 was $5,318. The addition of these operations added a total of 386 operational senior living units to be operated by the Company’s independent operating subsidiaries. Typically, subsidiaries of the Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. The fair value of assets for nine of the acquisitions was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions in accordance with Topic 805. The aggregate purchase price for these acquisitions was $593, mainly consisting of indefinite-lived intangible assets of $515. The fair value of assets for the remaining six acquisitions was concentrated in goodwill and as such, these transactions were classified as business acquisitions in accordance with Topic 805. The purchase price for the six business combinations was $4,725, mainly consisted of goodwill and indefinite-lived intangible assets of $4,710. The Company did not incur acquisition costs related to business combinations during the year ended December 31, 2018. 2017 Acquisitions During the year ended December 31, 2017, the Company expanded its operations with the addition of seven senior living operations, three home health agencies, three hospice agencies and one home care agency. The Company did not acquire any material assets or assume any liabilities, other than the tenant’s post-assumption rights and obligations under the senior living long-term leases. The aggregate purchase price for these acquisitions for the year ended December 31, 2017 was 12,059. The addition of these operations added 250 senior living units operated by the Company’s independent operating subsidiaries. Typically, subsidiaries of the Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. Unaudited Pro Forma Financial Information The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The independent operating subsidiaries acquired by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. From time to time, these acquisitions are more strategic in nature that may or may not have positive operational results. Financial information, especially with underperforming independent operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired independent operating subsidiaries. Revenue and income before tax included in the consolidated and combined statement of income relating to the business combinations was $17,006 and $3,036, respectively, during the year ended December 31, 2019. The unaudited pro forma financial information has been included for the businesses combinations during the year ended December 31, 2019. Business combinations during the year ended December 31, 2018 and 2017 were deemed immaterial and as such, no pro forma financial information has been included. The acquisitions during the year ended December 31, 2019 have been included in the December 31, 2019 consolidated and combined balance sheets of the Company, and the operating results have been included in the consolidated and combined statements of income of the Company since the dates the Company gained effective control. Revenues and operating costs were based on actual results from the prior operator or from regulatory filings where available. If actual results were not available, revenues and operating costs were estimated based on available partial operating results of the prior operator of the operation, or if no information was available, estimates were derived from the Company’s post-acquisition operating results for that particular operation. The unaudited pro forma information is not indicative of what the results of operations would have been if the business combinations had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends. The following tables represent unaudited pro forma results of consolidated and combined operations as if the business combinations in fiscal year 2019 had occurred at the beginning of 2018, after giving effect to certain adjustments. The unaudited pro forma information is not indicative of what the results of operations would have been if the acquisitions had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends. Unaudited Pro Forma Data Year Ended December 31, 2019 2018 Revenue $ 349,881 $ 315,127 Net income attributable to The Pennant Group, Inc. (a) $ 2,956 $ 16,690 (a) Net income attributable to The Pennant Group, Inc. for each of the years ended December 31, 2019 and 2018 includes a tax impact of 25.4% and 25.0%, which are the respective statutory tax rates. Subsequent Events Subsequent to December 31, 2019, the Company acquired one home health agency, one hospice agency and one senior living community. The aggregate purchase price for these acquisitions was $2,968. In connection with the acquisition of the senior living community, the Company entered into a new long-term “triple-net” lease with a subsidiary of Ensign. As of the date of this report, the preliminary allocation of the purchase price for the acquisitions acquired subsequent to December 31, 2019 were not completed as necessary valuation information was not yet available. As such, the determination whether these acquisitions should be classified as business combinations or asset acquisitions under ASC 805 will be determined upon completion of the allocation of the purchase price. Additionally, subsequent to December 31, 2019, the Company announced that a subsidiary of its home health and hospice portfolio company entered into an agreement to form a home health joint venture with Scripps Health, a leading nonprofit integrated health system based in San Diego, California. The finalization of the joint venture is subject to customary closing conditions and is expected to occur in the third quarter of 2020. Following the closing of the transaction, the joint venture will be managed by a Cornerstone affiliate and will provide home health services to patients throughout San Diego County and surrounding areas.

PROPERTY AND EQUIPMENT_NET

PROPERTY AND EQUIPMENT—NET	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT—NET	PROPERTY AND EQUIPMENT—NET Property and equipment, net consist of the following: Year Ended December 31, 2019 2018 Leasehold improvements $ 6,621 $ 4,299 Equipment 18,930 14,436 Furniture and fixtures 877 583 26,428 19,318 Less: accumulated depreciation (11,784) (8,860) Property and equipment, net $ 14,644 $ 10,458 Depreciation expense was $3,757, $2,863 and $2,444 for the years ended December 31, 2019, 2018 and 2017, respectively. See also Note 7, Acquisitions for information on acquisitions during the years ended December 31, 2019, 2018 and 2017.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS - NET	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS - NET	GOODWILL AND INTANGIBLE ASSETS—NET The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its goodwill impairment analysis for each reporting unit that constitutes a business for which (1) discrete financial information is produced and reviewed by operating segment management and (2) provides services that are distinct from the other components of the operating segment, in accordance with the provisions of ASC Topic 350, Intangibles-Goodwill and Other (“Topic 350”). Topic 350 provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a “Step 0” analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs “Step 1” of the traditional two-step goodwill impairment test by comparing the net assets of each reporting unit to their respective fair values. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. In the event a unit’s net assets exceed its fair value, an implied fair value of goodwill must be determined by assigning the unit’s fair value to each asset and liability of the unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. An impairment loss is measured by the difference between the goodwill carrying value and the implied fair value. The Company anticipates the the majority to total goodwill recognized will be fully deductible for tax purposes as of December 31, 2019. The following table represents activity in goodwill by segment as of and for the year ended December 31, 2019: Home Health and Hospice Services Senior Living Services Total December 31, 2017 $ 24,322 $ 3,642 $ 27,964 Additions 2,872 2,872 Purchase price adjustment 56 56 December 31, 2018 27,250 3,642 30,892 Additions 10,341 — 10,341 December 31, 2019 $ 37,591 $ 3,642 $ 41,233 Other indefinite-lived intangible assets consist of the following: Year Ended December 31, 2019 2018 Trade name $ 355 $ 328 Medicare and Medicaid licenses 33,107 24,808 Total $ 33,462 $ 25,136 Definite-lived intangible assets consist of the following: December 31, 2019 December 31, 2018 Intangible Weighted Average Life (Years) Gross Carrying Accumulated Amortization Net Gross Carrying Accumulated Amortization Net Patient base 0.7 $ 611 $ (611) $ — $ 591 $ (573) $ 18 Customer relationships 2.6 470 (425) 45 470 (410) 60 Total $ 1,081 $ (1,036) $ 45 $ 1,061 $ (983) $ 78 Amortization expense was $53, $101 and $100 for the years ended December 31, 2019, 2018 and 2017, respectively. Estimated amortization expense for each of the periods ending December 31, is as follows: Year Amount 2020 $ 14 2021 14 2022 14 2023 3 $ 45

OTHER ACCRUED LIABILITIES

OTHER ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
OTHER ACCRUED LIABILITIES	OTHER ACCRUED LIABILITIES Other accrued liabilities consist of the following: December 31, 2019 December 31, 2018 Refunds payable $ 2,152 $ 1,905 Deferred revenue 1,937 1,542 Resident deposits 6,292 6,310 Property taxes 1,130 932 Other 2,400 1,682 Other accrued liabilities $ 13,911 $ 12,371 Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Deferred revenue occurs when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to residents and a small portion consists of non-refundable deposits recognized into revenue over a period of time.

DEBT

DEBT	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
DEBT	DEBT Long-term debt, net consists of the following: Year Ended December 31, 2019 2018 Revolving Credit Facility $ 20,000 $ — Less: unamortized debt issuance costs (1,474) — Long-term debt, net $ 18,526 $ — On October 1, 2019, Pennant entered into a Credit Agreement, which provides for a revolving credit facility with a syndicate of banks with a borrowing capacity of $75.0 million (the “Revolving Credit Facility”). The interest rates applicable to loans under the Revolving Credit Facility are, at the Company’s election, either (i) Adjusted LIBOR (as defined in the Credit Agreement) plus a margin ranging from 2.5% to 3.5% per annum or (ii) Base Rate plus a margin ranging from 1.5% to 2.5% per annum, in each case based on the ratio of Consolidated Total Net Debt to Consolidated EBITDA (each, as defined in the Credit Agreement). In addition, Pennant will pay a commitment fee on the undrawn portion of the commitments under the Revolving Credit Facility that is estimated to be 0.6% per annum. The Company is not required to repay any loans under the Credit Agreement prior to maturity in 2024, other than to the extent the outstanding borrowings exceed the aggregate commitments under the Credit Agreement. As of December 31, 2019, the Company’s weighted average interest rate on its outstanding debt was 4.7%. As of December 31, 2019, we had availability on our Revolving Credit Facility of $51,987, which is net of outstanding letters of credit of $3,013. The fair value of the Company’s Revolver approximates carrying value, due to the short-term nature and variable interest rates. The fair value of this debt is categorized within Level 2 of the fair value hierarchy based on the observable market borrowing rates. The Credit Agreement is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material independent operating subsidiaries as well as a first lien on substantially all of each material operating subsidiary's personal property. The Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Agreement, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of a maximum Consolidated Total Net Debt to Consolidated EBITDA ratio (which cannot be above 2.50:1.00) (the “Leverage Ratio”), and a minimum interest/rent coverage ratio (which cannot be below 1.50:1.00). However, if the aggregate consideration paid in connection with permitted acquisitions consummated during any six ten

OPTIONS AND AWARDS

OPTIONS AND AWARDS	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
OPTIONS AND AWARDS	OPTIONS AND AWARDS For all periods prior to the Spin-Off, employees of the Company participated in Ensign's stock-based compensation plans. The compensation expense recorded by the Company included the expense associated with these employees, as well as an allocation of stock-based compensation of certain Ensign employees who provided general and administrative services on our behalf. Outstanding options held by employees of the Company under the Ensign stock plans (collectively the “Ensign Plans”) and outstanding options and restricted stock awards under the Company Subsidiary Equity Plan (together with the Ensign Plans the “Pre-Spin Plans”) were modified and replaced with Pennant awards at the Spin-Off date. Additionally, in connection with the Spin-Off, the Company issued new options and restricted stock awards to Pennant and Ensign employees under the 2019 Omnibus Incentive Plan (the “ OIP ” ) and Long-Term Incentive Plan (the “ LTIP ”, together referred to as the “Pennant Plans” ). Under the Ensign Plans and the Pennant Plans, stock-based payment awards, including employee stock options, restricted stock awards (“RSA”), and restricted stock units (“RSU” and together with RSA, “Restricted Stock”) are issued based on estimated fair value. The following disclosures represent share-based compensation expense relating to the Ensign and Pennant Plans, including awards to employees of the Company’s subsidiaries and an allocation of costs from employees in the Service Center prior to the Spin-Off, and total share-based compensation after the Spin-Off. Total share-based compensation expense for all of the Plans for the years ended December 31, 2019, 2018 and 2017: Year Ended December 31, 2019 2018 2017 Prior to the Spin-Off: Total share-based compensation $ 1,395 $ 2,382 $ 2,298 Following the Spin-Off: Share-based compensation expense related to stock options 315 — — Share-based compensation expense related to Restricted Stock 1,589 — — Share-based compensation expense related to Restricted Stock to non-employee directors 83 — — Total share-based compensation $ 3,382 $ 2,382 $ 2,298 In future periods, the Company expects to recognize approximately $4,245 and $23,530 in share-based compensation expense for unvested options and unvested Restricted Stock, respectively, which were outstanding as of December 31, 2019. Future share-based compensation expense will be recognized over 4.4 and 3.2 weighted average years for unvested options and restricted stock awards, respectively. Stock Options Under the Pennant Plans, options granted to employees of the subsidiaries of Pennant generally vest over five ten The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for share-based payment awards under the Plans. Determining the appropriate fair-value model and calculating the fair value of stock-based awards at the grant date requires considerable judgment, including estimating stock price volatility and expected option life. The Company develops estimates based on historical data and market information, which can change significantly over time. The fair value of each option is estimated on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions for stock options granted after the Spin-Off: Grant Year Options Granted Risk-Free Interest Rate Expected Life (a) Expected Volatility (b) Dividend Yield 2019 667 1.6 % 6.5 34.6 % — % (a) Under the midpoint method, the expected option life is the midpoint between the contractual option life and the average vesting period for the options being granted. This resulted in an expected option life of 6.5 years for the options granted on October 1, 2019. (b) Because the Company ’ s equity shares have been traded for a relatively short period of time, expected volatility assumption was based on the volatility of related industry stocks. For the year ended December 31, 2019, the following represents the exercise price and fair value displayed at grant date for stock option grants: Grant Year Granted Weighted Average Exercise Price Weighted Average Fair Value of Options 2019 667 $ 15.23 $ 5.7 The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the year ended December 31, 2019 and therefore, the intrinsic value was $0 at date of grant. The following table represents the employee stock option activity during the year ended December 31, 2019: Number of Options Outstanding Weighted Average Exercise Price Number of Options Vested Weighted Average Exercise Price of Options Vested Converted at Spin-Off on October 1, 2019 (a) 917 $ 5.68 586 $ 4.73 Granted 667 15.23 Exercised (7) 4.64 Forfeited (4) 14.07 December 31, 2019 1,573 $ 9.71 607 $ 4.80 (a) Represents outstanding awards under the Ensign stock plans, which were converted on October 1, 2019. The aggregate intrinsic value of options outstanding, vested, unvested and exercised as of and for the period ended December 31, 2019 is as follows: Options December 31, 2019 Outstanding $ 35,835 Vested 17,176 Unvested 18,659 Exercised $ 189 The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. There were 966 unvested and outstanding options at December 31, 2019. The weighted average contractual life for options outstanding, vested and expected to vest at December 31, 2019 was 7.40 years. Restricted Stock Awards Under the Pennant Plans, the Company granted Restricted Stock to Pennant employees, Ensign employees, and to non-employee directors. All awards were granted at an issued price of $0 and generally vest between three five Non-Vested Restricted Awards Weighted Average Grant Date Fair Value Converted at Spin-Off on October 1, 2019 (a) 329 $ 11.20 Granted 1,484 15.10 Vested (19) 10.68 Forfeited (1) 8.24 December 31, 2019 1,793 $ 14.44 a) Represents outstanding awards under the Ensign stock plans, which were converted on October 1, 2019. During the years ended December 31, 2019 and 2018, the Company repurchased 599 and 865 shares of common stock, respectively, under the Subsidiary Equity Plan for $2,687 and $1,972, respectively. The Company subsequently sold 534 and 865 shares years ended December 31, 2019 and 2018, and received net proceeds of $2,293 and $1,972, respectively. The shares of common stock under the Subsidiary Equity Plan that were repurchased but not sold by the Company were included in the assets transferred by Ensign to Pennant as part of the internal reorganization effected in connection with and as part of the Spin-Off.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
LEASES	LEASES The Company’s independent operating subsidiaries lease 52 senior living communities and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five . The existing leases with subsidiaries of Ensign are for initial terms of between 14 to 16 years. In addition to rent, each of the operating companies are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all community maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Fifteen of the Company’s affiliated senior living communities, excluding the communities that are operated under the Ensign Leases (as defined herein), are operated under two separate master lease arrangements. Under these master leases, a breach at a single community could subject one or more of the other communities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases and master leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the master lease without the consent of the landlord. Impact of New Leases Guidance The adoption of Topic 842 did not result in adjustments to the Company’s condensed combined statements of income. The components of operating lease cost, are as follows: Year Ended December 31, 2019 Operating Lease Costs: Facility Rent—cost of services $ 32,011 Office Rent—cost of services 2,964 Rent—cost of services (a) $ 34,975 General and administrative expense 162 Variable lease cost (b) 4,608 (a) Rent—cost of services includes non-cash lease expense of $220 for the year ended December 31, 2019. Rent—cost of services includes short-term leases, which are immaterial. (b) Represents variable lease cost for operating leases. Includes property taxes and insurance, common area maintenance, and consumer price index increases, incurred as part of our triple net lease, and is included in cost of services for the year ended December 31, 2019. The following table shows the lease maturity analysis for all leases as of December 31, 2019: Year Amount 2020 $ 37,087 2021 36,654 2022 36,131 2023 35,712 2024 35,359 Thereafter 387,878 Total lease payments 568,821 Less: present value adjustments (252,492) Present value of total lease liabilities 316,329 Less: current lease liabilities (12,285) Long-term operating lease liabilities $ 304,044 Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at each lease’s commencement date to determine each lease's operating lease liability. As of December 31, 2019, the weighted average remaining lease term is 16.0 years and the weighted average discount rate is 8.1%. On October 1, 2019, in connection with the Spin-Off, the Company amended its master lease agreements with Ensign and certain other landlords. These amendments modified the rental payments, the initial term or both. In accordance with Topic 842, the amended lease agreements are considered to be modified and subjected to lease modification guidance. The right-of-use asset and lease liabilities related to these agreements were remeasured based on the change in the lease conditions such as rent payment and lease terms. The incremental borrowing rate was also adjusted to mirror the revised lease terms which became effective at the date of the modification, which was the date of the Spin-Off. The Ensign Leases and new third-party master lease agreements have initial terms ranging between ten Rent expense for operating leases classified under Topic 840 for the years ended December 31, 2018 and 2017 were $31,199 and $31,304, respectively. Future minimum lease payments for all leases under Topic 840 as of December 31, 2018 were as follows: Year Amount 2019 $ 33,055 2020 32,181 2021 31,625 2022 31,241 2023 30,896 Thereafter 243,333 Total lease payments $ 402,331

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Prior the date of the Spin-Off, the Company's operations were included in Ensign’s U.S. federal and state income tax returns and all income taxes were paid by Ensign. Additionally, prior to the date of the Spin-Off, income tax expense and other income tax related information contained in these Consolidated and Combined Financial Statements were presented on a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company were a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts were reasonable. However, the Company's Consolidated and Combined Financial Statements may not necessarily reflect the Company’s income tax expense or tax payments in the future, or what its tax amounts would have been if the Company had been a stand-alone company during the periods presented. The Company recorded a prepaid expense for income taxes in connection with the income tax returns the Company will file for the three month period from October 1, 2019 through December 31, 2019. Effective January 1, 2018, the Tax Act reduced the corporate rate from 35.0% to 21.0%. The Company has adopted ASU 2018-05, Taxes (Topic 740): Amendments to SEC Paragraph Pursuant to SEC Staff Accounting Bulletin No. 118 , which allows the Company to record provisional amounts during the period of enactment. Any changes to the provisional amounts are recorded as adjustments to the provision for income taxes in the period the amounts are determined. During the year ended December 31, 2017, the Company recognized a provisional reduction to income tax expense of $315 to reflect the revaluation of the Company’s net deferred tax liabilities based on the U.S. federal tax rate of 21%. In accordance with SAB 118, the Tax Act related income tax effects that were initially reported as provisional estimates were refined as additional analysis was performed. As of December 31, 2018, the Company had completed its accounting for the tax effects of the enactment of the Tax Act. The provision for income taxes for the years ended December 31, 2019, 2018 and 2017 is summarized as follows: Year Ended December 31, 2019 2018 2017 Current: Federal $ 562 $ 3,223 $ 3,550 State 278 915 649 840 4,138 4,199 Deferred: Federal 1,070 226 1,305 State 175 (12) 186 1,245 214 1,491 Adjustment to deferred taxes for tax rate change — — (315) Total income tax expense $ 2,085 $ 4,352 $ 5,375 A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2019, 2018 and 2017, respectively, is comprised as follows: Year Ended December 31, 2019 2018 2017 Income tax expense at statutory rate 21.0 % 21.0 % 35.0 % State income taxes - net of federal benefit 6.8 3.5 3.5 Non-deductible expenses 2.6 0.4 0.3 Transaction costs 41.2 — — Tax credits (1.6) — — Equity compensation (30.0) (2.9) (1.4) Revaluation of deferred — (0.2) (2.0) Other adjustments (0.4) (0.7) (0.5) Total income tax provision 39.6 % 21.1 % 34.9 % The Company's completion of the Spin-Off resulted in the Company not being able to deduct approximately $10,300 of the related transaction costs, which increased the effective tax rate significantly and affected all items that were impacted by this exclusion. This increase was partially offset by a favorable impact of tax benefits related to equity compensation. The Company’s deferred tax assets and liabilities as of December 31, 2019 and 2018 are summarized below. Year Ended December 31, 2019 2018 Deferred tax assets (liabilities): Accrued expenses $ 2,670 $ 2,964 Allowance for doubtful accounts 869 857 State taxes 27 178 Lease liabilities 83,076 — Insurance 137 — Total deferred tax assets 86,779 3,999 Depreciation and amortization (6,107) (4,357) Prepaid expenses (594) (240) Right of use asset (82,181) — Other liabilities — (14) Total deferred tax liabilities (88,882) (4,611) Net deferred tax liabilities, included in other long-term liabilities $ (2,103) $ (612) As of December 31, 2019, the Company has $830 of net operating loss carryforwards for federal income tax purposes which are available to reduce future federal taxable income, if any, over an indefinite period. The utilization of those net operating loss carryforwards is limited to 80% of taxable income in any given year. The federal statutes of limitations on the Company’s 2015, 2014, and 2013 income tax years lapsed during the third quarter of 2019, 2018, and 2017, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2019 and 2018 had no impact on the Company’s unrecognized tax benefits.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Regulatory Matters - The Company provides services in complex and highly regulated industries. The Company’s compliance with applicable federal, state and local laws and regulations governing these industries may be subject to governmental review and adverse findings may result in significant regulatory action, which could include sanctions, damages, fines, penalties (many of which may not be covered by insurance), and even exclusion from government programs. The Company is a party to various regulatory and other governmental audits and investigations in the ordinary course of business and cannot predict the ultimate outcome of any federal or state regulatory survey, audit or investigation. While governmental audits and investigations are the subject of administrative appeals, the appeals process, even if successful, may take several years to resolve. The Department of Justice, The Centers for Medicare and Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses. The Company believes that it is presently in compliance in all material respects with all applicable laws and regulations. Cost-Containment Measures - Government and third party payors have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company. Indemnities - From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of agencies and communities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer, (iii) certain Ensign lending agreements, and (iv) certain agreements with management, directors and employees, under which the subsidiaries of the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s combined balance sheets for any of the periods presented. Litigation - The Company’s businesses involve a significant risk of liability given the age and health of the patients and residents served by its independent operating subsidiaries. The Company, its operating companies, and others in the industry may be subject to a number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company is routinely subjected to these claims in the ordinary course of business, including potential claims related to patient care and treatment, professional negligence and class actions, as well as employment related claims. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, the defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the False Claims Act (the “FCA”) and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which it does conduct business. In May 2009, Congress passed the Fraud Enforcement and Recovery Act ("FERA") which made significant changes to the FCA, expanding the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, healthcare providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government, including the retention of any government overpayment. The Patient Protection and Affordable Care Act of 2010 (the “ACA”) supplemented FERA by imposing an affirmative obligation on healthcare providers to return an overpayment to CMS within 60 days of “identification” or the date any corresponding cost report is due, whichever is later. According to CMS’s February 12, 2016, final rule with respect to Medicare Parts A and B, providers have an obligation to proactively exercise “reasonable diligence” to identify overpayments. The 60-day clock begins to run after the reasonable diligence period has concluded, which may take, at most, six months from the receipt of credible information. Retention of any overpayment beyond this period may create liability under the FCA. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is generally no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing. The Company cannot predict or provide any assurance as to the possible outcome of any litigation. If any litigation were to proceed, and the Company and its operating companies are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, the Company’s business, financial condition and results of operations and cash flows could be materially and adversely affected. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries going forward under a corporate integrity agreement and/or other arrangement with the government. Medicare Revenue Recoupments - The Company is subject to probe reviews relating to Medicare services, billings and potential overpayments by Unified Program Integrity Contractors (UPIC), Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC), Supplemental Medical Review Contractors (SMRC) and Medicaid Integrity Contributors (MIC) programs, each of the foregoing collectively referred to as “Reviews.” As of December 31, 2019, eight of the Company’s independent operating subsidiaries had Reviews scheduled, on appeal or in dispute resolution process, both pre- and post-payment. The Company anticipates that these probe reviews will increase in frequency in the future. If an operation fails an initial or subsequent Review, the operation could then be subject to extended Review, suspension of payment, or extrapolation of the identified error rate to all billing in the same time period. As of December 31, 2019, and through the filing of this Annual Report on Form 10-K, the Company’s independent operating subsidiaries have responded to the Reviews that are currently ongoing, on appeal or in dispute resolution process and the Company has no probable or estimable contingencies. Insurance - Prior to the Spin-Off Ensign was partially self-insured for healthcare, general and professional liability, and workers’ compensation, and historically allocated premium expense to all subsidiaries of Ensign in its accounting records. To reflect all of the insurance costs, quarterly actuary determined adjustments were allocated to the Company based on the proportional historical premium expense. No self-insurance accruals were allocated to the Company as these accruals represent the obligations of Ensign. In connection with the Spin-Off, the Company purchased insurance through a third-party to replace the coverage provided by Ensign’s self-insured policies. While the Company maintains various insurance programs to cover these risks, it retains risk for a substantial portion of potential claims for general and professional liability and workers’ compensation. The Company does not retain risk related to its employee health plans. The Company recognizes obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. The general and professional liability insurance has a retention limit of $250 per claim and the workers’ compensation insurance has a retention limit of $150 per claim, except for policies held in Texas and Washington which are subject to state insurance and possesses their own limits. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. Additionally, the Company has partially indemnified Ensign for general and professional liabilities incurred prior to the Spin-off but not reported until after that date and included that amount in the accrual below. The following table presents details of the Company's insurance programs, including amounts accrued for the periods indicated in other accrued liabilities and other long-term liabilities in our accompanying balance sheets. The amounts accrued below represent the total estimated liability for individual claims that are less than our noted insurance coverage amounts, which includes outstanding claims and claims incurred but not reported. Year Ended December 31, 2019 2018 Type of Insurance General and professional liability $ 521 $ — Workers’ compensation 433 — Total estimated liability 954 — Less: long-term portion (774) — Current portion of estimated liability, included in other accrued liabilities $ 180 $ — Concentrations Credit Risk - The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s gross receivables from the Medicare and Medicaid programs accounted for approximately 74.3% and 72.4% of its total gross accounts receivable as of December 31, 2019 and December 31, 2018, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 55.6%, 53.1%, and 51.4% of the Company's revenue for the years ended December 31, 2019, 2018 and 2017, respectively.

VALUATION AND QUALIFYING ACCOUN

VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
VALUATION AND QUALIFYING ACCOUNTS	Schedule II Valuation and Qualifying Accounts Balances at Beginning of Year Impact of ASC 606 Adoption (a) Additions Charged to Costs and Expenses Deductions Balances at End of Year (In thousands) Year Ended December 31, 2017 Allowance for doubtful accounts $ (3,675) $ — $ (3,374) $ 1,991 $ (5,058) Year Ended December 31, 2018 Allowance for doubtful accounts $ (5,058) $ 4,590 $ (346) $ 198 $ (616) Year Ended December 31, 2019 Allowance for doubtful accounts $ (616) $ — $ (858) $ 797 $ (677) (a) Subsequent to the adoption of ASC 606, the majority of what was previously presented as allowance for doubtful accounts related to bad debt expense has been incorporated as an implicit price concession factored into net revenue and accounts receivable. Allowance for doubtful accounts as of December 31, 2019 represents the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts and other currently available evidence. All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the combined financial statements or notes thereto.

BASIS OF PRESENTATION AND SUM_2

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation - The accompanying consolidated and combined financial statements of the Company (the “Financial Statements”) reflect the Company’s financial position, results of operations and cash flows as the business was operated as part of Ensign prior to the Spin-Off, and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the regulations of the Securities and Exchange Commission (“SEC”). Prior to the Spin-Off, the combined financial statements were prepared on a stand-alone basis and derived from the consolidated financial statements and accounting records of Ensign. Management believes that the Financial Statements reflect, in all material respects, all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position, results of operations, and cash flows for the periods presented in conformity with GAAP applicable to the annual period.
Consolidation	All intercompany transactions and balances between the various legal entities comprising the Company have been eliminated in consolidation. The consolidated and combined statements of income reflect income that is attributable to the Company and the noncontrolling interest. The Company consists of various limited liability companies and corporations established to operate home health, hospice, home care, and senior living operations. The Financial Statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Revenue was derived from transactional information specific to the Company’s services provided. The costs in the consolidated and combined statements of income reflect direct costs and allocated costs prior to the Spin-Off.
Cost Allocation	Cost Allocation - The Financial Statements include allocations of costs for certain shared services provided to the Company by Ensign subsidiaries prior to the Spin-Off on October 1, 2019. Such allocations include, but are not limited to, executive management, accounting, human resources, information technology, compliance, legal, payroll, insurance, tax, treasury, and other general and administrative items. These costs were allocated to the Company on a basis of revenue, location, employee count, or other measures. These cost allocations are reflected within general and administrative expense in the consolidated and combined statements of income, including for share-based compensation expenses disclosed in Note 12 , Options and Awards Ensign’s external debt and related interest expense were not allocated to the Company for any of the periods presented as no portion of the borrowings were assumed by the Company as part of the Spin-Off. All interest incurred by the Company was subsequent to the Spin-Off. Prior to the Spin-Off, employees of the Company’s subsidiaries participated in Ensign’s equity-based incentive plans (the “Ensign Plans”) and the Cornerstone Subsidiary Equity plan (the “Subsidiary Equity Plan”). Share-based compensation includes the expense attributable to employees of the Company’s subsidiaries who participated in the Ensign Plans, as well as the allocated cost related to Ensign subsidiaries’ employees that participated in the Ensign Plans. Share-based compensation related to Ensign subsidiaries’ employees that participated in the Ensign Plans were allocated on the basis of revenue. All share-based compensation related to the Subsidiary Equity Plan was recognized in the Financial Statements and, therefore, no cost allocation was necessary. Prior to the Spin-Off, share-based compensation costs associated with the Subsidiary Equity Plan awards was initially measured at fair value at the grant date and was expensed as non-cash compensation over the vesting term.
Estimates and Assumptions	Estimates and Assumptions - The preparation of Financial Statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, cost allocations, intangible assets and goodwill, right-of-use assets and lease liabilities for leases greater than 12 months, and income taxes. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition - On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“Topic 606”) applying the modified retrospective method. The adoption of Topic 606 did not have a material impact on the measurement nor on the recognition of revenue of contracts, for which all revenue had not been recognized, as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of retained earnings at the beginning of 2018.Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct within the context of the contract. Additionally, there may be ancillary services which are not included in the rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered. Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net service revenue in the period such variances become known. Revenue from the Medicare and Medicaid programs accounted for 55.6%, 53.1%, and 51.4% of the Company’s revenue for the years ended December 31, 2019, 2018 and 2017, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. Disaggregation of Revenue The Company disaggregates revenue from contracts with its patients by reportable operating segments and payors. The Company has determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in Note 5, Revenue and Accounts Receivable . The Company’s service specific revenue recognition policies are as follows: Home Health Revenue Medicare Revenue Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments. The Company adjusts Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and the Company’s estimate of the average percentage complete based on visits performed. Non-Medicare Revenue Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. Non-episodic Based Revenue - Revenue is recognized on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable. Hospice Revenue Revenue is recognized on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are calculated as daily rates for each of the levels of care the Company delivers. Revenue is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and an increase to other accrued liabilities. Senior Living Revenue The Company has elected the lessor practical expedient within Topic 842 and recognizes, measures, presents, and discloses the revenue for services rendered under the Company’s senior living residency agreements based upon the predominant component, either the lease or non-lease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements each have the same timing and pattern of transfer. The Company recognizes revenue under Topic 606 for its senior residency agreements, for which it has determined that the non-lease components of such residency agreements are the predominant component of each such contract. Practical Expedients and Exemptions As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs (“Topic 340”), and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
Cash and cash equivalents	Cash and cash equivalents - Cash and cash equivalents consist of bank term deposits and therefore approximates fair value. The Company places its cash with high credit quality financial institutions. Prior to the Spin-off the Company participated in a cash management program with Ensign where net cash activity was included in the net parent investment.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts - Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance.
Property and Equipment	Property and Equipment - Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets - The Company reviews the carrying value of long-lived assets that are held and used in the independent operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiary to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.
Intangible Assets and Goodwill	Intangible Assets and Goodwill - Definite-lived intangible assets consist primarily of patient base and customer relationships. Patient base is amortized over a period of four months to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition when acquired. Customer relationships are amortized between one seven The Company’s indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2019, 2018 and 2017. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its goodwill impairment analysis for each reporting unit that constitutes a business for which (1) discrete financial information is produced and reviewed by operating segment management and (2) provides services that are distinct from the other components of the operating segment, in accordance with the provisions of ASC Topic 350, Intangibles-Goodwill and Other (“Topic 350”). Topic 350 provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a “Step 0” analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs “Step 1” of the traditional two-step goodwill impairment test by comparing the net assets of each reporting unit to their respective fair values. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. In the event a unit’s net assets exceed its fair value, an implied fair value of goodwill must be determined by assigning the unit’s fair value to each asset and liability of the unit. The excess of the fair value of the
Fair Value of Financial Instruments	Fair Value of Financial Instruments - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. The Company determines fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Income Taxes	Income Taxes - Prior to the date of the Spin-off, the Company’s operations have been included in Ensign’s U.S. federal and state income tax returns and all income taxes have been paid by subsidiaries of Ensign. Also prior to the date of the Spin-off, income tax expense and other income tax related information contained in these Financial Statements were presented using a separate tax return approach. Under this approach, the provision for income taxes represents income tax paid or payable for the current year plus the change in deferred taxes during the year calculated as if the Company was a stand-alone taxpayer filing hypothetical income tax returns. Management believes that the assumptions and estimates used to determine these tax amounts are reasonable. However, the Company’s Financial Statements may not necessarily reflect its income tax expense or tax payments in the future, or what tax amounts would have been if the Company had been a stand-alone company for the entire period presented. Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
Noncontrolling Interest	Noncontrolling Interest - Prior to the Spin-Off, the Company presented the noncontrolling interest and the amount of consolidated net income attributable to the Company in its Financial Statements. The carrying amount of the noncontrolling interest was adjusted by an allocation of subsidiary earnings based on ownership interest prior to the Spin-Off. The noncontrolling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off and thus, will no longer be allocated a portion of earnings
Share-Based Compensation	Share-Based Compensation - The Company measures and recognizes compensation expense for all share-based payment awards, including employee stock options, made to employees and Pennant’s directors based on estimated fair values,
Invested Capital	Invested Capital - The net parent investment on the consolidated and combined balance sheets represents Ensign’s historical investment in the Company, the net effect of transactions with, and allocations from, Ensign and the Company’s accumulated earnings. Invested capital was reclassified into additional paid-in-capital at the date of the Spin-Off.
Earnings Per Share	Earnings Per Share - For all prior periods presented, the earnings per share included on the accompanying Consolidated and Combined Statements of Income was calculated based on the 27,834 shares of Pennant common stock distributed on October 1, 2019 in conjunction with the Spin-Off, including shares related to the conversion of the noncontrolling interest. Prior to October 1, 2019, Pennant did not have any issued and outstanding common stock. The same number of shares was used to calculate basic and diluted earnings per share since no Pennant employee equity awards were outstanding prior to the Spin-Off. Basic and diluted net income per share are computed by dividing net income by the weighted average number of outstanding common shares during the period. In the basic and diluted earnings per share calculations, net income is equal to net income attributable to The Pennant Group, Inc. adjusted to include net income attributable to noncontrolling interest. Net income attributable to the noncontrolling interest has been included in the numerator for all periods as the non-controlling subsidiary interest included in the Financial Statements was converted into common shares of Pennant concurrent with the distribution to Ensign stockholders at the date of the Spin-Off .
Recent Accounting Pronouncements	Recent Accounting Pronouncements - Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration. Recent Accounting Standards Adopted by the Company Leases and Leasehold Improvements - The Company leases senior living communities and commercial office space. In February 2016, the FASB established Topic 842, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines. On January 1, 2019, the Company adopted ASC Topic 842, Leases (“Topic 842”), using the modified retrospective transition method. Leases for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC Topic 840, Leases (“Topic 840” ). The Company has elected the package of practical expedients permitted under the transition guidance which allows us to not reassess (1) initial direct costs, (2) lease classification for existing or expired leases, and (3) lease definition for existing or expired contracts as of the effective date of January 1, 2019. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheets and recognize those lease payments in the condensed combined statements of income on a straight-line basis over the lease term. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. Operating leases are included in operating lease assets, current operating lease liabilities and noncurrent operating lease liabilities on the Company's consolidated and combined balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term excludes lease renewals because the renewal rents are not at a bargain, there are no economic penalties for the Company not to renew the lease, and it is not reasonably assured that the Company will exercise the extension options. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements. The adoption of this standard resulted in recognition of right-of-use assets and lease liabilities of $240,090 and $241,453, respectively, on the Company’s combined balance sheet as of January 1, 2019. Neither net deferred tax assets nor equity were impacted as a result of the adoption of this standard. The standard did not materially affect its consolidated and combined net earnings or have a notable impact on liquidity. See further discussion at Note 13, Leases . Prior to the adoption of Topic 842, the Company recognized revenue related to its senior living residency agreements in accordance with the provisions of Topic 840. Subsequent to the adoption of Topic 842, lessors are required to separately recognize and measure the lease component of a contract with a customer utilizing the provisions of Topic 842 and the non-lease components utilizing the provisions of Topic 606, Revenue from Contracts with Customers. To separately account for the components, the transaction price is allocated among the components based upon the estimated stand-alone selling prices of the components. Additionally, certain components of a contract which were previously included within the lease element recognized in accordance with Topic 842 prior to the adoption of Topic 842 (such as common area maintenance services, other basic services, and executory costs) are recognized as non-lease components subject to the provisions of Topic 606 subsequent to the adoption of Topic 842. Entities are required to recognize a cumulative effect adjustment to beginning retained earnings as of the initial application date of Topic 842 for changes to amounts recognized for these certain components for the transition from Topic 840 to Topic 606. However, entities are permitted to elect the practical expedient under ASU 2018-11, Leases (“ASU 2018-11”), allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. Entities that elect to utilize the lease/non-lease component combination practical expedient under ASU 2018-11 upon initial application of Topic 842 are required to apply the practical expedient to all new and existing transactions within a class of underlying assets that qualify for the expedient as of the initial application date with a cumulative effect adjustment to beginning retained earnings as of the initial application date for any changes recognized related to existing transactions. Upon adoption of Topic 842, the Company elected the lessor practical expedient within ASU 2018-11. The Company recognizes revenue under resident agreements based upon the predominant component, either the lease or non-lease component, of the contracts rather than allocating the consideration and separately accounting for it under Topic 842 and Topic 606. The Company has concluded that the non-lease components of the agreements governing its senior living communities are the predominant component of the contract; therefore, the Company recognizes revenue for these agreements under Topic 606. The timing and pattern of revenue recognition is substantially the same as that in effect prior to the adoption of Topics 606 and 842. Stock Compensation - In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (“ASU 2018-07”), which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of ASC Topic 718, Compensation-Stock Compensation (“Topic 718”), to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606. The Company adopted ASU 2018-07 effective January 1, 2019. The adoption of ASU 2018-07 did not have a material impact on Interim Financial Statements and related disclosures. Accounting Standards Recently Issued but Not Yet Adopted by the Company Financial Accounting Standards Board, or FASB, Accounting Standards Update, or ASU, 2018-13 “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” or ASU 2018-13 - In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company’s fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. FASB ASU, 2017-04 “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” or ASU 2017-04 - In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new guidance eliminates “Step 2” from the traditional two-step goodwill impairment test and redefines the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount, to a measure comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or “Step 2” of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company’s fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. FASB ASU 2016-13 “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” or ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ( “Topic 326”), which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. Topic 326 will be effective for fiscal years beginning after December 15, 2019, which will be the Company’s fiscal year 2020, and early adoption is permitted. The Company is performing its valuation and does not expect the standard to have a material impact on our consolidated financial statements.

COMPUTATION OF NET INCOME PER_2

COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Computation of basic and diluted net income per share	The following table sets forth the computation of basic and diluted net income per share for the periods presented: Year Ended December 31, 2019 2018 2017 Numerator: Net income attributable to The Pennant Group, Inc. $ 2,546 $ 15,684 $ 9,867 Add: net income attributable to noncontrolling interests 629 595 160 Net Income $ 3,175 $ 16,279 $ 10,027 Denominator: Weighted average shares outstanding for basic net income per share 27,838 27,834 27,834 Plus: incremental shares from assumed conversion (a) 1,748 — — Adjusted weighted average common shares outstanding for diluted income per share 29,586 27,834 27,834 Earnings Per Share: Basic net income per common share $ 0.11 $ 0.58 $ 0.36 Diluted net income per common share $ 0.11 $ 0.58 $ 0.36 (a) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were immaterial for the year ended December 31, 2019.

REVENUE AND ACCOUNTS RECEIVAB_2

REVENUE AND ACCOUNTS RECEIVABLE (Tables)	12 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer and Accounts Receivable [Abstract]
Revenue by major payor source	Revenue by payor for the years ended December 31, 2019, 2018 and 2017, is summarized in the following tables: Year Ended December 31, 2019 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 47,819 $ 93,933 $ — $ 141,752 41.9 % Medicaid 6,575 10,061 29,819 46,455 13.7 Subtotal 54,394 103,994 29,819 188,207 55.6 Managed care 27,711 1,536 — 29,247 8.6 Private and other (a) 18,837 152 102,088 121,077 35.8 Total revenue $ 100,942 $ 105,682 $ 131,907 $ 338,531 100.0 % (a) Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations. Year Ended December 31, 2018 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 42,091 $ 73,906 $ — $ 115,997 40.5 % Medicaid 4,680 7,729 23,624 36,033 12.6 Subtotal 46,771 81,635 23,624 152,030 53.1 Managed care 23,541 918 — 24,459 8.6 Private and other (a) 16,067 105 93,397 109,569 38.3 Total revenue $ 86,379 $ 82,658 $ 117,021 $ 286,058 100.0 % (a) Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations. Year Ended December 31, 2017 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 36,592 $ 61,422 $ — $ 98,014 39.0 % Medicaid 4,398 6,832 19,813 31,043 12.4 Subtotal 40,990 68,254 19,813 129,057 51.4 Managed care 21,058 765 — 21,823 8.7 Private and other (a) 10,997 339 88,775 100,111 39.9 Total revenue $ 73,045 $ 69,358 $ 108,588 $ 250,991 100.0 %
Accounts receivable	Accounts receivable as of December 31, 2019 and December 31, 2018 is summarized in the following table: December 31, 2019 December 31, 2018 Medicare $ 17,822 $ 11,457 Medicaid 6,579 6,692 Managed care 4,380 3,079 Private and other 4,079 3,857 Accounts receivable, gross 32,860 25,085 Less: allowance for doubtful accounts (677) (616) Accounts receivable, net $ 32,183 $ 24,469

BUSINESS SEGMENTS (Tables)

BUSINESS SEGMENTS (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment revenues by major payor source	Revenue by payor for the years ended December 31, 2019, 2018 and 2017, is summarized in the following tables: Year Ended December 31, 2019 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 47,819 $ 93,933 $ — $ 141,752 41.9 % Medicaid 6,575 10,061 29,819 46,455 13.7 Subtotal 54,394 103,994 29,819 188,207 55.6 Managed care 27,711 1,536 — 29,247 8.6 Private and other (a) 18,837 152 102,088 121,077 35.8 Total revenue $ 100,942 $ 105,682 $ 131,907 $ 338,531 100.0 % (a) Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations. Year Ended December 31, 2018 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 42,091 $ 73,906 $ — $ 115,997 40.5 % Medicaid 4,680 7,729 23,624 36,033 12.6 Subtotal 46,771 81,635 23,624 152,030 53.1 Managed care 23,541 918 — 24,459 8.6 Private and other (a) 16,067 105 93,397 109,569 38.3 Total revenue $ 86,379 $ 82,658 $ 117,021 $ 286,058 100.0 % (a) Private and other payors in our home health and hospice services segment includes revenue from all payors generated in our home care operations. Year Ended December 31, 2017 Home Health and Hospice Services Home Health Services Hospice Services Senior Living Services Total Revenue Revenue % Medicare $ 36,592 $ 61,422 $ — $ 98,014 39.0 % Medicaid 4,398 6,832 19,813 31,043 12.4 Subtotal 40,990 68,254 19,813 129,057 51.4 Managed care 21,058 765 — 21,823 8.7 Private and other (a) 10,997 339 88,775 100,111 39.9 Total revenue $ 73,045 $ 69,358 $ 108,588 $ 250,991 100.0 %
Financial data combined by business segment	The following table presents certain financial information regarding our reportable segments, general and administrative expenses are not allocated to the reportable segments and are included in “All Other” for the years ended December 31, 2019, 2018 and 2017: Home Health and Hospice Services Senior Living Services All Other Total Year Ended December 31, 2019 Revenue $ 206,624 $ 131,907 $ — $ 338,531 Segment Adjusted EBITDAR from Operations $ 33,354 $ 47,344 $ (18,591) $ 62,107 Year Ended December 31, 2018 Revenue $ 169,037 $ 117,021 $ — $ 286,058 Segment Adjusted EBITDAR from Operations $ 26,427 $ 47,230 $ (16,191) $ 57,466 Year Ended December 31, 2017 Revenue $ 142,403 $ 108,588 $ — $ 250,991 Segment Adjusted EBITDAR from Operations $ 21,007 $ 44,230 $ (12,643) $ 52,594
Reconciliation of total Combined Adjusted EBITDAR from Operations for our reportable segments to Combined Income from Operations	Year Ended December 31, 2019 2018 2017 Segment Adjusted EBITDAR from Operations $ 62,107 $ 57,466 $ 52,594 Less: Depreciation and amortization 3,810 2,964 2,544 Rent—cost of services 34,975 31,199 31,304 Adjustments to Segment EBITDAR from Operations: Less: Costs at start-up operations (a) 483 129 478 Share-based compensation expense (b) 3,382 2,382 2,298 Acquisition related costs (c) 665 — — Spin-off related transaction costs (d) 13,219 756 — Transition services costs (e) 532 — — Operating results of closed operations (f) — — 728 Add: Net income attributable to noncontrolling interest 629 595 160 Consolidated and Combined Income from Operations $ 5,670 $ 20,631 $ 15,402 (a) Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations. (b) Share-based compensation expense incurred which is included in cost of services and general and administrative expense. (c) Acquisition related costs that are not capitalizable. (d) Costs incurred related to the Spin-Off are included in general and administrative expense. (e) A portion of the costs incurred under the Transition Services Agreement (as defined in Note 3, Related Party Transactions and Net Parent Investment ) identified as redundant or nonrecurring that are included in general and administrative expense. Total fees under incurred under the Transition Services agreement were $2,982 for the year ended December 31, 2019.

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Unaudited pro forma results of condensed combined operations	The following tables represent unaudited pro forma results of consolidated and combined operations as if the business combinations in fiscal year 2019 had occurred at the beginning of 2018, after giving effect to certain adjustments. The unaudited pro forma information is not indicative of what the results of operations would have been if the acquisitions had actually occurred at the beginning of the periods presented and is not intended as a projection of future results or trends. Unaudited Pro Forma Data Year Ended December 31, 2019 2018 Revenue $ 349,881 $ 315,127 Net income attributable to The Pennant Group, Inc. (a) $ 2,956 $ 16,690

PROPERTY AND EQUIPMENT_NET (Tab

PROPERTY AND EQUIPMENT—NET (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and equipment, net	Property and equipment, net consist of the following: Year Ended December 31, 2019 2018 Leasehold improvements $ 6,621 $ 4,299 Equipment 18,930 14,436 Furniture and fixtures 877 583 26,428 19,318 Less: accumulated depreciation (11,784) (8,860) Property and equipment, net $ 14,644 $ 10,458

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - NET (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Activity in goodwill by segment	The following table represents activity in goodwill by segment as of and for the year ended December 31, 2019: Home Health and Hospice Services Senior Living Services Total December 31, 2017 $ 24,322 $ 3,642 $ 27,964 Additions 2,872 2,872 Purchase price adjustment 56 56 December 31, 2018 27,250 3,642 30,892 Additions 10,341 — 10,341 December 31, 2019 $ 37,591 $ 3,642 $ 41,233
Other indefinite-lived intangible assets	Other indefinite-lived intangible assets consist of the following: Year Ended December 31, 2019 2018 Trade name $ 355 $ 328 Medicare and Medicaid licenses 33,107 24,808 Total $ 33,462 $ 25,136
Definite-lived intangible assets	Definite-lived intangible assets consist of the following: December 31, 2019 December 31, 2018 Intangible Weighted Average Life (Years) Gross Carrying Accumulated Amortization Net Gross Carrying Accumulated Amortization Net Patient base 0.7 $ 611 $ (611) $ — $ 591 $ (573) $ 18 Customer relationships 2.6 470 (425) 45 470 (410) 60 Total $ 1,081 $ (1,036) $ 45 $ 1,061 $ (983) $ 78
Estimated amortization expense	Estimated amortization expense for each of the periods ending December 31, is as follows: Year Amount 2020 $ 14 2021 14 2022 14 2023 3 $ 45

OTHER ACCRUED LIABILITIES (Tabl

OTHER ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Other accrued liabilities	Other accrued liabilities consist of the following: December 31, 2019 December 31, 2018 Refunds payable $ 2,152 $ 1,905 Deferred revenue 1,937 1,542 Resident deposits 6,292 6,310 Property taxes 1,130 932 Other 2,400 1,682 Other accrued liabilities $ 13,911 $ 12,371

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of long-term debt	Long-term debt, net consists of the following: Year Ended December 31, 2019 2018 Revolving Credit Facility $ 20,000 $ — Less: unamortized debt issuance costs (1,474) — Long-term debt, net $ 18,526 $ —

OPTIONS AND AWARDS (Tables)

OPTIONS AND AWARDS (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Total share-based compensation expense	Total share-based compensation expense for all of the Plans for the years ended December 31, 2019, 2018 and 2017: Year Ended December 31, 2019 2018 2017 Prior to the Spin-Off: Total share-based compensation $ 1,395 $ 2,382 $ 2,298 Following the Spin-Off: Share-based compensation expense related to stock options 315 — — Share-based compensation expense related to Restricted Stock 1,589 — — Share-based compensation expense related to Restricted Stock to non-employee directors 83 — — Total share-based compensation $ 3,382 $ 2,382 $ 2,298
Stock options granted fair value assumptions	The fair value of each option is estimated on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions for stock options granted after the Spin-Off: Grant Year Options Granted Risk-Free Interest Rate Expected Life (a) Expected Volatility (b) Dividend Yield 2019 667 1.6 % 6.5 34.6 % — % (a) Under the midpoint method, the expected option life is the midpoint between the contractual option life and the average vesting period for the options being granted. This resulted in an expected option life of 6.5 years for the options granted on October 1, 2019. (b) Because the Company ’ s equity shares have been traded for a relatively short period of time, expected volatility assumption was based on the volatility of related industry stocks.
Stock option grant date exercise price and fair value	For the year ended December 31, 2019, the following represents the exercise price and fair value displayed at grant date for stock option grants: Grant Year Granted Weighted Average Exercise Price Weighted Average Fair Value of Options 2019 667 $ 15.23 $ 5.7
Employee stock option activity	The following table represents the employee stock option activity during the year ended December 31, 2019: Number of Options Outstanding Weighted Average Exercise Price Number of Options Vested Weighted Average Exercise Price of Options Vested Converted at Spin-Off on October 1, 2019 (a) 917 $ 5.68 586 $ 4.73 Granted 667 15.23 Exercised (7) 4.64 Forfeited (4) 14.07 December 31, 2019 1,573 $ 9.71 607 $ 4.80 (a) Represents outstanding awards under the Ensign stock plans, which were converted on October 1, 2019.
Aggregate intrinsic value of options outstanding, vested, expected to vest and exercisable	The aggregate intrinsic value of options outstanding, vested, unvested and exercised as of and for the period ended December 31, 2019 is as follows: Options December 31, 2019 Outstanding $ 35,835 Vested 17,176 Unvested 18,659 Exercised $ 189
Summary of non-vested restricted stock awards	A summary of the status of Pennant’s non-vested Restricted Stock, and changes during the period ended December 31, 2019, is presented below: Non-Vested Restricted Awards Weighted Average Grant Date Fair Value Converted at Spin-Off on October 1, 2019 (a) 329 $ 11.20 Granted 1,484 15.10 Vested (19) 10.68 Forfeited (1) 8.24 December 31, 2019 1,793 $ 14.44 a) Represents outstanding awards under the Ensign stock plans, which were converted on October 1, 2019.

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Components of operating lease cot	The components of operating lease cost, are as follows: Year Ended December 31, 2019 Operating Lease Costs: Facility Rent—cost of services $ 32,011 Office Rent—cost of services 2,964 Rent—cost of services (a) $ 34,975 General and administrative expense 162 Variable lease cost (b) 4,608 (a) Rent—cost of services includes non-cash lease expense of $220 for the year ended December 31, 2019. Rent—cost of services includes short-term leases, which are immaterial. (b) Represents variable lease cost for operating leases. Includes property taxes and insurance, common area maintenance, and consumer price index increases, incurred as part of our triple net lease, and is included in cost of services for the year ended December 31, 2019.
Future minimum lease payments	The following table shows the lease maturity analysis for all leases as of December 31, 2019: Year Amount 2020 $ 37,087 2021 36,654 2022 36,131 2023 35,712 2024 35,359 Thereafter 387,878 Total lease payments 568,821 Less: present value adjustments (252,492) Present value of total lease liabilities 316,329 Less: current lease liabilities (12,285) Long-term operating lease liabilities $ 304,044
Future minimum lease payments	Future minimum lease payments for all leases under Topic 840 as of December 31, 2018 were as follows: Year Amount 2019 $ 33,055 2020 32,181 2021 31,625 2022 31,241 2023 30,896 Thereafter 243,333 Total lease payments $ 402,331

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Provision for income taxes on continuing operations	The provision for income taxes for the years ended December 31, 2019, 2018 and 2017 is summarized as follows: Year Ended December 31, 2019 2018 2017 Current: Federal $ 562 $ 3,223 $ 3,550 State 278 915 649 840 4,138 4,199 Deferred: Federal 1,070 226 1,305 State 175 (12) 186 1,245 214 1,491 Adjustment to deferred taxes for tax rate change — — (315) Total income tax expense $ 2,085 $ 4,352 $ 5,375
Reconciliation of federal statutory rate to effective tax rate	A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2019, 2018 and 2017, respectively, is comprised as follows: Year Ended December 31, 2019 2018 2017 Income tax expense at statutory rate 21.0 % 21.0 % 35.0 % State income taxes - net of federal benefit 6.8 3.5 3.5 Non-deductible expenses 2.6 0.4 0.3 Transaction costs 41.2 — — Tax credits (1.6) — — Equity compensation (30.0) (2.9) (1.4) Revaluation of deferred — (0.2) (2.0) Other adjustments (0.4) (0.7) (0.5) Total income tax provision 39.6 % 21.1 % 34.9 %
Deferred tax assets and liabilities	The Company’s deferred tax assets and liabilities as of December 31, 2019 and 2018 are summarized below. Year Ended December 31, 2019 2018 Deferred tax assets (liabilities): Accrued expenses $ 2,670 $ 2,964 Allowance for doubtful accounts 869 857 State taxes 27 178 Lease liabilities 83,076 — Insurance 137 — Total deferred tax assets 86,779 3,999 Depreciation and amortization (6,107) (4,357) Prepaid expenses (594) (240) Right of use asset (82,181) — Other liabilities — (14) Total deferred tax liabilities (88,882) (4,611) Net deferred tax liabilities, included in other long-term liabilities $ (2,103) $ (612)

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Summary of Insurance Liability	The following table presents details of the Company's insurance programs, including amounts accrued for the periods indicated in other accrued liabilities and other long-term liabilities in our accompanying balance sheets. The amounts accrued below represent the total estimated liability for individual claims that are less than our noted insurance coverage amounts, which includes outstanding claims and claims incurred but not reported. Year Ended December 31, 2019 2018 Type of Insurance General and professional liability $ 521 $ — Workers’ compensation 433 — Total estimated liability 954 — Less: long-term portion (774) — Current portion of estimated liability, included in other accrued liabilities $ 180 $ —

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Details)	Dec. 31, 2019facilityagency	Oct. 01, 2019
Segment Reporting Information [Line Items]
Spin-Off transaction, distribution ratio		0.50
Home Health and Hospice Services
Segment Reporting Information [Line Items]
Number of service providers | agency	63
Senior Living Services
Segment Reporting Information [Line Items]
Number of operating facilities | facility	52

BASIS OF PRESENTATION AND SUM_3

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) shares in Thousands, $ in Thousands	Oct. 01, 2019	Dec. 31, 2019	Oct. 01, 2019	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019
Accounting Policies [Abstract]
General and administrative expense				$ 23,710	$ 35,135	$ 18,843	$ 14,463
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation		$ 3,382	$ 1,395		3,382	2,382	2,298
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets		316,328			316,328
Lease liabilities		$ 316,329			316,329
General and administrative expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation					$ 2,769	$ 1,900	$ 1,823
Minimum
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives					3 years
Maximum
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives					15 years
Patient base | Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization period					4 months
Patient base | Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization period					8 months
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization period					1 year
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization period					7 years
Common stock
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Shares issued (in shares)	27,834				27,834
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets								$ 240,090
Lease liabilities								$ 241,453

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND NET PARENT INVESTMENT (Details) $ in Thousands	Oct. 01, 2019	Dec. 31, 2019USD ($)facilityproperty	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Senior Living Services
Related Party Transaction [Line Items]
Number of operating facilities | facility		52
Senior Living Services | Minimum
Related Party Transaction [Line Items]
Lease term		5 years
Senior Living Services | Maximum
Related Party Transaction [Line Items]
Lease term		21 years
Related party
Related Party Transaction [Line Items]
Cost of services		$ 3,166	$ 2,996	$ 3,023
Related party | Operating lease, rent expense
Related Party Transaction [Line Items]
Expenses from transactions with related party		11,292	$ 10,363	$ 11,364
Related party | Transition Services Agreement
Related Party Transaction [Line Items]
Expenses from transactions with related party		2,982
Term	2 years
Term, extension	5 months
Related party | Recognition of tax benefits related to Tax Matters Agreement
Related Party Transaction [Line Items]
Amounts of related party transaction		$ 291
Related party | Senior Living Services
Related Party Transaction [Line Items]
Number of operating facilities | property		29
Related party | Senior Living Services | Minimum
Related Party Transaction [Line Items]
Lease term		14 years
Related party | Senior Living Services | Maximum
Related Party Transaction [Line Items]
Lease term		16 years

COMPUTATION OF NET INCOME PER_3

COMPUTATION OF NET INCOME PER COMMON SHARE - NARRATIVE (Details) shares in Thousands	Oct. 01, 2019shares	Dec. 31, 2019shares
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Spin-Off transaction, distribution ratio	0.50
Common stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Shares issued (in shares)	27,834	27,834
Ensign Group Shareholders | Common stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Shares issued (in shares)	26,674
Noncontrolling Interest Holders | Common stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Shares issued (in shares)	1,160

COMPUTATION OF NET INCOME PER_4

COMPUTATION OF NET INCOME PER COMMON SHARE - RECONCILIATION (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income attributable to The Pennant Group, Inc.	$ 2,546	$ 15,684	$ 9,867
Add: net income attributable to noncontrolling interests	629	595	160
Net income	$ 3,175	$ 16,279	$ 10,027
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares outstanding for basic net income per share (in shares)	27,838	27,834	27,834
Plus: incremental shares from assumed conversion	1,748	0	0
Adjusted weighted average common shares outstanding for diluted income per share (in share)	29,586	27,834	27,834
Earnings Per Share, Basic and Diluted [Abstract]
Basic net income per share (in dollars per share)	$ 0.11	$ 0.58	$ 0.36
Diluted net income per share (in dollars per share)	$ 0.11	$ 0.58	$ 0.36

REVENUE AND ACCOUNTS RECEIVAB_3

REVENUE AND ACCOUNTS RECEIVABLE - NARRATIVE (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Senior Living Services
Disaggregation of Revenue [Line Items]
Payment terms	Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.
Customer concentration risk | Revenue
Disaggregation of Revenue [Line Items]
Revenue %	100.00%	100.00%	100.00%
Customer concentration risk | Revenue | Medicare and medicaid
Disaggregation of Revenue [Line Items]
Revenue %	55.60%	53.10%	51.40%

REVENUE AND ACCOUNTS RECEIVAB_4

REVENUE AND ACCOUNTS RECEIVABLE - REVENUE BY MAJOR PAYOR (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 338,531	$ 286,058	$ 250,991
Revenue | Customer concentration risk
Disaggregation of Revenue [Line Items]
Revenue %	100.00%	100.00%	100.00%
Medicare and medicaid
Disaggregation of Revenue [Line Items]
Revenue	$ 188,207	$ 152,030	$ 129,057
Medicare and medicaid | Revenue | Customer concentration risk
Disaggregation of Revenue [Line Items]
Revenue %	55.60%	53.10%	51.40%
Medicare
Disaggregation of Revenue [Line Items]
Revenue	$ 141,752	$ 115,997	$ 98,014
Medicare | Revenue | Customer concentration risk
Disaggregation of Revenue [Line Items]
Revenue %	41.90%	40.50%	39.00%
Medicaid
Disaggregation of Revenue [Line Items]
Revenue	$ 46,455	$ 36,033	$ 31,043
Medicaid | Revenue | Customer concentration risk
Disaggregation of Revenue [Line Items]
Revenue %	13.70%	12.60%	12.40%
Managed care
Disaggregation of Revenue [Line Items]
Revenue	$ 29,247	$ 24,459	$ 21,823
Managed care | Revenue | Customer concentration risk
Disaggregation of Revenue [Line Items]
Revenue %	8.60%	8.60%	8.70%
Private and other
Disaggregation of Revenue [Line Items]
Revenue	$ 121,077	$ 109,569	$ 100,111
Private and other | Revenue | Customer concentration risk
Disaggregation of Revenue [Line Items]
Revenue %	35.80%	38.30%	39.90%
Home Health and Hospice Services | Home Health Services
Disaggregation of Revenue [Line Items]
Revenue	$ 100,942	$ 86,379	$ 73,045
Home Health and Hospice Services | Home Health Services | Medicare and medicaid
Disaggregation of Revenue [Line Items]
Revenue	54,394	46,771	40,990
Home Health and Hospice Services | Home Health Services | Medicare
Disaggregation of Revenue [Line Items]
Revenue	47,819	42,091	36,592
Home Health and Hospice Services | Home Health Services | Medicaid
Disaggregation of Revenue [Line Items]
Revenue	6,575	4,680	4,398
Home Health and Hospice Services | Home Health Services | Managed care
Disaggregation of Revenue [Line Items]
Revenue	27,711	23,541	21,058
Home Health and Hospice Services | Home Health Services | Private and other
Disaggregation of Revenue [Line Items]
Revenue	18,837	16,067	10,997
Home Health and Hospice Services | Hospice Services
Disaggregation of Revenue [Line Items]
Revenue	105,682	82,658	69,358
Home Health and Hospice Services | Hospice Services | Medicare and medicaid
Disaggregation of Revenue [Line Items]
Revenue	103,994	81,635	68,254
Home Health and Hospice Services | Hospice Services | Medicare
Disaggregation of Revenue [Line Items]
Revenue	93,933	73,906	61,422
Home Health and Hospice Services | Hospice Services | Medicaid
Disaggregation of Revenue [Line Items]
Revenue	10,061	7,729	6,832
Home Health and Hospice Services | Hospice Services | Managed care
Disaggregation of Revenue [Line Items]
Revenue	1,536	918	765
Home Health and Hospice Services | Hospice Services | Private and other
Disaggregation of Revenue [Line Items]
Revenue	152	105	339
Senior Living Services
Disaggregation of Revenue [Line Items]
Revenue	131,907	117,021
Senior Living Services | Medicare and medicaid
Disaggregation of Revenue [Line Items]
Revenue	29,819	23,624	19,813
Senior Living Services | Medicare
Disaggregation of Revenue [Line Items]
Revenue	0	0	0
Senior Living Services | Medicaid
Disaggregation of Revenue [Line Items]
Revenue	29,819	23,624	19,813
Senior Living Services | Managed care
Disaggregation of Revenue [Line Items]
Revenue	0	0	0
Senior Living Services | Private and other
Disaggregation of Revenue [Line Items]
Revenue	$ 102,088	$ 93,397	$ 88,775

REVENUE AND ACCOUNTS RECEIVAB_5

REVENUE AND ACCOUNTS RECEIVABLE - ACCOUNTS RECEIVABLE (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts Receivable [Abstract]
Accounts receivable, gross	$ 32,860	$ 25,085
Less: allowance for doubtful accounts	(677)	(616)
Accounts receivable, net	32,183	24,469
Medicare
Accounts Receivable [Abstract]
Accounts receivable, gross	17,822	11,457
Medicaid
Accounts Receivable [Abstract]
Accounts receivable, gross	6,579	6,692
Managed care
Accounts Receivable [Abstract]
Accounts receivable, gross	4,380	3,079
Private and other
Accounts Receivable [Abstract]
Accounts receivable, gross	$ 4,079	$ 3,857

BUSINESS SEGMENTS - NARRATIVE (

BUSINESS SEGMENTS - NARRATIVE (Details)	Dec. 31, 2019agencyfacility
Home Health and Hospice Services
Segment Reporting Information [Line Items]
Number of service providers | agency	63
Senior Living Services
Segment Reporting Information [Line Items]
Number of operating facilities | facility	52

BUSINESS SEGMENTS - FINANCIAL D

BUSINESS SEGMENTS - FINANCIAL DATA (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 338,531	$ 286,058	$ 250,991
Segment Adjusted EBITDAR from Operations	62,107	57,466	52,594
Senior Living Services
Segment Reporting Information [Line Items]
Revenue	131,907	117,021
Operating segments | Home Health and Hospice Services
Segment Reporting Information [Line Items]
Revenue	206,624	169,037	142,403
Segment Adjusted EBITDAR from Operations	33,354	26,427	21,007
Operating segments | Senior Living Services
Segment Reporting Information [Line Items]
Revenue	131,907	117,021	108,588
Segment Adjusted EBITDAR from Operations	47,344	47,230	44,230
All Other
Segment Reporting Information [Line Items]
Revenue	0	0	0
Segment Adjusted EBITDAR from Operations	$ (18,591)	$ (16,191)	$ (12,643)

BUSINESS SEGMENTS - INCOME FROM

BUSINESS SEGMENTS - INCOME FROM OPERATIONS (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Oct. 01, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting [Abstract]
Segment Adjusted EBITDAR from Operations			$ 62,107	$ 57,466	$ 52,594
Less: Depreciation and amortization			3,810	2,964	2,544
Rent—cost of services			34,975
Rent—cost of services				31,199	31,304
Less: Costs at start-up operations			483	129	478
Share-based compensation expense	$ 3,382	$ 1,395	3,382	2,382	2,298
Acquisition related costs			665	0	0
Spin-off related transaction costs			13,219	756	0
Transaction services costs			532	0	0
Operating results of closed operations			0	0	728
Add: net income attributable to noncontrolling interests			629	595	160
Income from operations			$ 5,670	$ 20,631	$ 15,402

ACQUISITIONS - NARRATIVE (Detai

ACQUISITIONS - NARRATIVE (Details) $ in Thousands	2 Months Ended	12 Months Ended
	Mar. 04, 2020USD ($)stand-alone_senior_living_operationhome_health_agencyhospice_agency	Dec. 31, 2019USD ($)home_care_agencyhome_health_agencysenior_living_unitstand-alone_senior_living_operationhospice_agency	Dec. 31, 2018USD ($)acquisitionhome_health_agencyhospice_agencyhome_care_agencysenior_living_unitstand-alone_senior_living_operation	Dec. 31, 2017USD ($)hospice_agencyhome_care_agencysenior_living_unitstand-alone_senior_living_operationhome_health_agency
Business Acquisition [Line Items]
Business combination and asset acquisition, purchase price		$ 18,780	$ 5,318	$ 12,059
Business combination, preliminary allocation of purchase price, goodwill		41,233	30,892	27,964
Business combination, acquisition costs		665	0	0
Subsequent event
Business Acquisition [Line Items]
Business combination and asset acquisition, purchase price	$ 2,968
Asset acquisitions 2019
Business Acquisition [Line Items]
Asset acquisition, purchase price		20
Asset acquisitions 2018
Business Acquisition [Line Items]
Asset acquisition, purchase price			$ 593
Asset acquisition, number of acquisitions | acquisition			9
Asset acquisition, preliminary allocation of purchase price, indefinite-lived intangible assets			$ 515
Business acquisitions 2019
Business Acquisition [Line Items]
Business combination, purchase price		18,760
Business combination, preliminary allocation of purchase price, goodwill		10,341
Preliminary allocation of purchase price, indefinite-lived intangible assets		8,326
Business combination, acquisition costs		611
Revenue		17,006
Net income (loss) before taxes		3,036
Business acquisitions 2018
Business Acquisition [Line Items]
Business combination, purchase price			4,725
Preliminary allocation of purchase price, indefinite-lived intangible assets			$ 4,710
Business combination, number of acquisitions | acquisition			6
Home Health and Hospice Services
Business Acquisition [Line Items]
Business combination, preliminary allocation of purchase price, goodwill		$ 37,591	$ 27,250	$ 24,322
Home Health and Hospice Services | Home Health Services
Business Acquisition [Line Items]
Number of businesses acquired and assets acquisitions | home_health_agency			4	3
Home Health and Hospice Services | Home Health Services | Subsequent event
Business Acquisition [Line Items]
Number of businesses acquired and assets acquisitions | home_health_agency	1
Home Health and Hospice Services | Home Health Services | Business acquisitions 2019
Business Acquisition [Line Items]
Number of businesses acquired | home_health_agency		2
Home Health and Hospice Services | Hospice Services
Business Acquisition [Line Items]
Number of businesses acquired and assets acquisitions | hospice_agency			2	3
Home Health and Hospice Services | Hospice Services | Subsequent event
Business Acquisition [Line Items]
Number of businesses acquired and assets acquisitions | hospice_agency	1
Home Health and Hospice Services | Hospice Services | Business acquisitions 2019
Business Acquisition [Line Items]
Number of businesses acquired | hospice_agency		5
Home Health and Hospice Services | Home Care
Business Acquisition [Line Items]
Number of businesses acquired and assets acquisitions | home_care_agency			2	1
Home Health and Hospice Services | Home Care | Business acquisitions 2019
Business Acquisition [Line Items]
Number of businesses acquired | home_care_agency		2
Senior Living Services
Business Acquisition [Line Items]
Number of units (in units) | senior_living_unit		143	386	250
Business combination, preliminary allocation of purchase price, goodwill		$ 3,642	$ 3,642	$ 3,642
Number of businesses acquired and assets acquisitions | stand-alone_senior_living_operation			7	7
Senior Living Services | Subsequent event
Business Acquisition [Line Items]
Number of businesses acquired and assets acquisitions | stand-alone_senior_living_operation	1
Senior Living Services | Asset acquisitions 2019
Business Acquisition [Line Items]
Number of asset acquisitions | stand-alone_senior_living_operation		2

ACQUISITIONS - UNAUDITED PRO FO

ACQUISITIONS - UNAUDITED PRO FORMA (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition, Pro Forma Information [Abstract]
Revenue	$ 349,881	$ 315,127
Net income attributable to New Ventures	$ 2,956	$ 16,690
Statutory tax rate	25.40%	25.00%

PROPERTY AND EQUIPMENT_NET (Det

PROPERTY AND EQUIPMENT—NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 26,428	$ 19,318
Less: accumulated depreciation	(11,784)	(8,860)
Property and equipment, net	14,644	10,458
Depreciation	3,757	2,863	$ 2,444
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6,621	4,299
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	18,930	14,436
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 877	$ 583

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - NET - ACTIVITY IN GOODWILL (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 30,892	$ 27,964
Additions	10,341	2,872
Purchase price adjustment		56
Goodwill, ending balance	41,233	30,892
Home Health and Hospice Services
Goodwill [Roll Forward]
Goodwill, beginning balance	27,250	24,322
Additions	10,341	2,872
Purchase price adjustment		56
Goodwill, ending balance	37,591	27,250
Senior Living Services
Goodwill [Roll Forward]
Goodwill, beginning balance	3,642	3,642
Additions	0
Purchase price adjustment
Goodwill, ending balance	$ 3,642	$ 3,642

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - NET - INDEFINITE-LIVED INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	$ 33,462	$ 25,136
Trade name
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	355	328
Medicare and Medicaid licenses
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	$ 33,107	$ 24,808

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - NET - DEFINITE-LIVED INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying	$ 1,081	$ 1,061
Accumulated Amortization	(1,036)	(983)
Definitive-lived intangible assets, net	45	78
Amortization expense	$ 53	101	$ 100
Patient base
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	8 months 12 days
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying	$ 611	591
Accumulated Amortization	(611)	(573)
Definitive-lived intangible assets, net	$ 0	18
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	2 years 7 months 6 days
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying	$ 470	470
Accumulated Amortization	(425)	(410)
Definitive-lived intangible assets, net	$ 45	$ 60

GOODWILL AND INTANGIBLE ASSET_6

GOODWILL AND INTANGIBLE ASSETS - NET - ESTIMATED AMORTIZATION EXPENSE (Details) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2020	$ 14
2021	14
2022	14
2023	3
Definitive-lived intangible assets, net	$ 45	$ 78

OTHER ACCRUED LIABILITIES (Deta

OTHER ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Other Accrued Liabilities, Current [Abstract]
Refunds payable	$ 2,152	$ 1,905
Deferred revenue	1,937	1,542
Resident deposits	6,292	6,310
Property taxes	1,130	932
Other	2,400	1,682
Other accrued liabilities	$ 13,911	$ 12,371

DEBT - SCHEDULE OF LONG-TERM DE

DEBT - SCHEDULE OF LONG-TERM DEBT (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Less: unamortized debt issuance costs	$ (1,474)	$ 0
Long-term debt, net	18,526	0
Revolving credit facility | Line of credit
Debt Instrument [Line Items]
Revolving Credit Facility	$ 20,000	$ 0

DEBT - NARRATIVE (Details)

DEBT - NARRATIVE (Details) - Line of credit	Oct. 01, 2019USD ($)quarter	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Revolving credit facility
Debt Instrument [Line Items]
Borrowing capacity	$ 75,000,000
Commitment fee on undrawn portion	0.60%
Weighted average interest rate		4.70%
Borrowing availability		$ 51,987,000
Leverage Ratio, maximum	2.50
Interest/rent coverage ratio, minimum	1.50
Leverage Ratio, acquisition consummated, consecutive months	6 months
Leverage Ratio, acquisition consummated, aggregate consideration paid	$ 20,000,000
Leverage Ratio, increased maximum	3
Leverage Ratio, increased maximum, term | quarter	3
Leverage Ratio less than then-applicable maximum Leverage Ratio, minimum	0.25
Leverage Ratio less than then-applicable maximum Leverage Ratio, minimum, term | quarter	2
Liquidity to Aggregate Revolving Commitment Amount ratio, maximum	10.00%
Liquidity to Aggregate Revolving Commitment Amount ratio, maximum, term	10 days
Debt outstanding		$ 20,000,000	$ 0
Revolving credit facility | Minimum | LIBOR
Debt Instrument [Line Items]
Margin		2.50%
Revolving credit facility | Minimum | Base Rate
Debt Instrument [Line Items]
Margin		1.50%
Revolving credit facility | Maximum | LIBOR
Debt Instrument [Line Items]
Margin		3.50%
Revolving credit facility | Maximum | Base Rate
Debt Instrument [Line Items]
Margin		2.50%
Letters of credit
Debt Instrument [Line Items]
Letters of credit outstanding		$ 3,013,000

OPTIONS AND AWARDS - SHARE-BASE

OPTIONS AND AWARDS - SHARE-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Oct. 01, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 3,382	$ 1,395	$ 3,382	$ 2,382	$ 2,298
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	315			0	0
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	1,589			0	0
Non-employee director | Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 83			$ 0	$ 0

OPTIONS AND AWARDS - NARRATIVE

OPTIONS AND AWARDS - NARRATIVE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of subsidiary shares	$ 2,687	$ 1,972	$ 0
Proceeds from sale of subsidiary shares	2,293	$ 1,972	$ 0
The Ensign Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested options, cost not yet recognized	$ 4,245
Options, grant date intrinsic value (in dollars per share)	$ 0
Options, unvested and outstanding (in shares)	966
Weighted average contractual life for options outstanding, vested and expected to vest	7 years 4 months 24 days
The Ensign Plans | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested options and stock awards, cost net yet recognized, period for recognition	4 years 4 months 24 days
Options, vesting percent per year	20.00%
Options, expiration period	10 years
The Ensign Plans | Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested stock awards, cost not yet recognized	$ 23,530
Unvested options and stock awards, cost net yet recognized, period for recognition	3 years 2 months 12 days
Vesting period	5 years
Issued price of awards granted (in dollars per share)	$ 0
Subsidiary Equity Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchased (in shares)	599	865
Repurchase of subsidiary shares	$ 2,687	$ 1,972
Shares issued (in shares)	534	865
Proceeds from sale of subsidiary shares	$ 2,293	$ 1,972
Minimum | Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum | Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

OPTIONS AND AWARDS - OPTIONS GR

OPTIONS AND AWARDS - OPTIONS GRANTED (Details) - The Ensign Plans shares in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019$ / sharesshares	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares) | shares	667
2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares) | shares		667
Weighted average exercise price (in dollars per share) | $ / shares	$ 15.23	$ 15.23
Weighted average fair value of options (in dollars per share) | $ / shares		$ 5.7
2019 | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free rate		1.60%
Expected life		6 years 6 months
Weighted average volatility		34.60%
Weighted average dividend yield		0.00%

OPTIONS AND AWARDS - EMPLOYEE S

OPTIONS AND AWARDS - EMPLOYEE STOCK OPTION ACTIVITY (Details) - The Ensign Plans shares in Thousands	3 Months Ended
	Dec. 31, 2019$ / sharesshares	Oct. 01, 2019$ / sharesshares
Number of Options Outstanding
Beginning balance, outstanding (in shares) | shares	917
Granted (in shares) | shares	667
Exercised (in shares) | shares	(7)
Forfeited (in shares) | shares	(4)
Ending balance, outstanding (in shares) | shares	1,573
Weighted Average Exercise Price
Beginning of period, weighted average exercise price (in dollars per share) | $ / shares	$ 5.68
Granted (in dollars per share) | $ / shares	15.23
Exercised (in dollars per share) | $ / shares	4.64
Forfeited (in dollars per share) | $ / shares	14.07
End of period, weighted average exercise price (in dollars per share) | $ / shares	$ 9.71
Number of options vested (in shares) | shares	607	586
Weighted average exercise price of options vested (in dollars per share) | $ / shares	$ 4.80	$ 4.73

OPTIONS AND AWARDS - AGGREGATE

OPTIONS AND AWARDS - AGGREGATE INTRINSIC VALUE OF OPTIONS (Details) - The Ensign Plans $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding	$ 35,835
Vested	17,176
Unvested	18,659
Exercised	$ 189

OPTIONS AND AWARDS - RESTRICTED

OPTIONS AND AWARDS - RESTRICTED STOCK AWARDS ACTIVITY (Details) - The Ensign Plans - Restricted stock awards shares in Thousands	3 Months Ended
	Dec. 31, 2019$ / sharesshares
Non-Vested Restricted Awards
Beginning balance, outstanding (in shares) | shares	329
Granted (in shares) | shares	1,484
Vested (in shares) | shares	(19)
Forfeited (in shares) | shares	(1)
Ending balance, outstanding (in shares) | shares	1,793
Weighted Average Grant Date Fair Value
Beginning of period, weighted average exercise price (in dollars per share) | $ / shares	$ 11.20
Granted (in dollars per share) | $ / shares	15.10
Vested (in dollars per share) | $ / shares	10.68
Forfeited (in dollars per share) | $ / shares	8.24
End of period, weighted average exercise price (in dollars per share) | $ / shares	$ 14.44

LEASES - NARRATIVE (Details)

LEASES - NARRATIVE (Details) $ in Thousands	Dec. 31, 2019facilityproperty	Oct. 01, 2019USD ($)
Lessee, Lease, Description [Line Items]
Weighted average remaining lease term	16 years
Weighted average discount rate	8.10%
Annual future minimum lease payments, initial increase due to modifications | $		$ 77,627
Minimum | Ensign
Lessee, Lease, Description [Line Items]
Lease term		10 years
Maximum | Ensign
Lessee, Lease, Description [Line Items]
Lease term		21 years
Senior Living Services
Lessee, Lease, Description [Line Items]
Number of properties under lease	52
Number of operating facilities	52
Senior Living Services | Minimum
Lessee, Lease, Description [Line Items]
Lease term	5 years
Senior Living Services | Maximum
Lessee, Lease, Description [Line Items]
Lease term	21 years
Senior Living Services | Related party
Lessee, Lease, Description [Line Items]
Number of operating facilities | property	29
Number of properties under lease, master lease agreement	15
Senior Living Services | Related party | Minimum
Lessee, Lease, Description [Line Items]
Lease term	14 years
Senior Living Services | Related party | Maximum
Lessee, Lease, Description [Line Items]
Lease term	16 years

LEASES - IMPACT OF NEW LEASES G

LEASES - IMPACT OF NEW LEASES GUIDANCE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Lease, Cost [Abstract]
Variable rent expense	$ 4,608
Amortization of deferred rent	220
Cost of services
Lease, Cost [Abstract]
Operating lease costs	34,975	$ 31,199	$ 31,304
Cost of services | Facility
Lease, Cost [Abstract]
Operating lease costs	32,011
Cost of services | Office
Lease, Cost [Abstract]
Operating lease costs	2,964
General and administrative expense
Lease, Cost [Abstract]
Operating lease costs	$ 162

LEASES - FUTURE MINIMUM LEASE P

LEASES - FUTURE MINIMUM LEASE PAYMENTS (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases, Under Adoption of ASC 842 [Abstract]
2020	$ 37,087
2021	36,654
2022	36,131
2023	35,712
2024	35,359
Thereafter	387,878
Total lease payments	568,821
Less: present value adjustments	(252,492)
Present value of total lease liabilities	316,329
Less: current lease liabilities	(12,285)
Long-term operating lease liabilities	$ 304,044
Leases, Before Adoption of ASC 842 [Abstract]
2019		$ 33,055
2020		32,181
2021		31,625
2022		31,241
2023		30,896
Thereafter		243,333
Total lease payments		$ 402,331

INCOME TAXES - NARRATIVE (Detai

INCOME TAXES - NARRATIVE (Details) - USD ($) $ in Thousands	Oct. 01, 2019	Dec. 31, 2017	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Tax Cuts and Jobs Act, provisional income tax expense recognized		$ 315
Nondeductible transaction costs	$ 10,300
Federal tax authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 830

INCOME TAXES - PROVISION FOR IN

INCOME TAXES - PROVISION FOR INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current:
Federal	$ 562	$ 3,223	$ 3,550
State	278	915	649
Current provision for income tax, total	840	4,138	4,199
Deferred:
Federal	1,070	226	1,305
State	175	(12)	186
Deferred provision for income tax, total	1,245	214	1,491
Adjustment to deferred taxes for tax rate change	0	0	(315)
Total income tax expense	$ 2,085	$ 4,352	$ 5,375

INCOME TAXES - TAX RATE RECONCI

INCOME TAXES - TAX RATE RECONCILIATION (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income tax expense at statutory rate	21.00%	21.00%	35.00%
State income taxes - net of federal benefit	6.80%	3.50%	3.50%
Non-deductible expenses	2.60%	0.40%	0.30%
Transaction costs	41.20%	0.00%	0.00%
Tax credits	(1.60%)	0.00%	0.00%
Equity compensation	(30.00%)	(2.90%)	(1.40%)
Revaluation of deferred	0.00%	(0.20%)	(2.00%)
Other adjustments	(0.40%)	(0.70%)	(0.50%)
Total income tax provision	39.60%	21.10%	34.90%

INCOME TAXES - DEFERRED TAX ASS

INCOME TAXES - DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets (liabilities):
Accrued expenses	$ 2,670	$ 2,964
Allowance for doubtful accounts	869	857
State taxes	27	178
Lease liabilities	83,076
Insurance	137	0
Total deferred tax assets	86,779	3,999
Depreciation and amortization	(6,107)	(4,357)
Prepaid expenses	(594)	(240)
Right of use asset	(82,181)
Other liabilities	0	(14)
Total deferred tax liabilities	(88,882)	(4,611)
Net deferred tax liabilities, included in other long-term liabilities	$ (2,103)	$ (612)

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - SUMMARY OF INSURANCE (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
General and professional liability	$ 521	$ 0
Workers’ compensation	433	0
Total estimated liability	954	0
Less: long-term portion	(774)	0
Current portion of estimated liability, included in other accrued liabilities	$ 180	$ 0

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details)	12 Months Ended
	Dec. 31, 2019USD ($)review	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Number of operating subsidiaries with reviews scheduled | review	8
General and professional liability, retention limit	$ 250,000
Workers' compensation, retention limit	$ 150,000
Revenue | Customer concentration risk
Concentration Risk [Line Items]
Concentration risk, percent	100.00%	100.00%	100.00%
Medicare and medicaid | Receivables | Customer concentration risk
Concentration Risk [Line Items]
Concentration risk, percent	74.30%	72.40%
Medicare and medicaid | Revenue | Customer concentration risk
Concentration Risk [Line Items]
Concentration risk, percent	55.60%	53.10%	51.40%

VALUATION AND QUALIFYING ACCO_2

VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for doubtful accounts - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balances at Beginning of Year	$ (616)	$ (5,058)	$ (3,675)
Impact of ASC 606 Adoption	0	4,590	0
Additions Charged to Costs and Expenses	(858)	(346)	(3,374)
Deductions	797	198	1,991
Balances at End of Year	$ (677)	$ (616)	$ (5,058)